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Advances to biomaterial polymers and surface coatings have markedly improved the safety and 
efficacy of extracorporeal devices, but there is untapped potential to use these surfaces to modulate 
blood cell behavior. Sepsis, a severe inflammatory response to infection that affects nearly 1 
million Americans per year, results in high levels of interleukin (IL-8) spilling into the circulatory 
system and diffusing into healthy tissue. Subsequently, circulating neutrophils become redirected 
into these healthy tissues, where they impair organ function. The focus of this work is the 
development of an extracorporeal device which can “reprogram” neutrophils using IL-8 
immobilized within the device. Additionally, a zwitterionic thromboresistant coating was 
developed to reduce platelet deposition in extracorporeal devices. 
 A mechanistic computational model was developed to study the role of IL-8 induced 
CXCR-1/2 neutrophil surface receptor downregulation and its role in the progression of sepsis. 
The findings suggest that a device which modulates receptor expression could reduce morbidity 
and mortality in sepsis, but there is also potential for harm if implemented incorrectly. Scaled 
prototypes of an extracorporeal device, which used immobilized IL-8 to reduce neutrophil 
migratory response, were constructed and evaluated. While significant downregulation of CXCR-
1 and CXCR-2 was achieved, this effect was insufficient to cause consistent migratory shutoff to 
IL-8 as measured by a Boyden chamber chemotaxis assay. Learnings from this testing were used 
to develop alternate device concepts which modulate leukocyte activity within an extracorporeal 
circuit. 
SURFACE COATINGS FOR MODIFYING CIRCULATING BLOOD CELL 
BEHAVIOR 
 
Alexander D. Malkin, PhD 
University of Pittsburgh, 2017 
ABSTRACT 
 v 
A zwitterionic macromolecule surface coating was developed to reduce platelet deposition 
on polymethylpentene (PMP) hollow fiber membranes (HFMs). Two techniques of PMP HFM 
functionalization and subsequent conjugation of sulfobetaine block copolymers were evaluated 
within scaled PMP fiber minimodules. Both fiber configurations resulted in an 80-95% reduction 
in adherent platelets from whole ovine blood, stability under shear stress, and uninhibited gas 
exchange performance relative to unmodified HFMs. Initial testing indicates this coating is 
effective on polycarbonate and poly(vinyl chloride), two other materials commonly found in 
extracorporeal circuits, which may allow for tip to tip coating of extracorporeal circuits. 
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1.0  INTRODUCTION 
Sepsis is a severe inflammatory response to infection that affects nearly 1 million 
Americans per year [1]. Importantly, much of the mortality and morbidity in sepsis is not due 
directly to the causal infection, but rather is due to sepsis induced organ failure. A normal innate 
immune response to infection involves local inflammation at the site of infection, and neutrophils 
migrating from the blood stream into the infected tissues due to chemical gradients of the 
chemokines such as Interleukin-8 (IL-8) released by macrophages. In sepsis, high levels of IL-8 at 
the site of infection spill into the circulatory system and move into healthy tissue. Subsequently, 
neutrophils become redirected into these healthy tissues where they impair organ function [2]. 
Potential treatments that indiscriminately suppress neutrophil activity have proven ineffective in 
sepsis [3,4] because they lead to immune suppression and the inability to clear the underlying 
infection. 
The work described in this dissertation will focus on development of an extracorporeal 
device that can “reprogram” neutrophils to attenuate their chemotactic response to IL-8 as a 
potential treatment for sepsis. Other background information, particularly pertaining to 
respiratory assist device, will be covered in the sixth chapter. The Neutrophil Reprogramming 
Device (NeRD) is essentially a hemodialyzer cartridge in which IL-8 is covalently bound to the 
inner lumens of the dialyzer fibers. Similar to hemodialysis, blood is perfused through the NeRD 
and neutrophils, which naturally marginate toward the fiber inner lumens, interact with the 
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immobilized IL-8 through CXCR-1 and CXCR-2 surface receptors, the same interaction that 
causes chemotaxis. As a result of the interaction, CXCR-1/2 surface expression on neutrophils is 
down-regulated, thus reducing the neutrophils chemotactic response to IL-8 as blood is perfused 
back into the patient. 
 
  
Figure 1. Schematic of Neutrophil Reprogramming Device (NeRD). 
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The neutrophils maintain the ability to target and eliminate bacteria in infected tissue 
through secondary CXCR-1/2 independent cell signaling pathways involving N-formyl-metyl-
leucyl-phenyl (fMLP), a byproduct of bacterial destruction. It is hypothesized that the reduced 
chemotactic response to IL-8 will reduce the redirection of neutrophils into healthy tissue and 
reduce sepsis induced organ failure. 
In addition to development and evaluation of the NeRD, a mechanistic computational 
model was developed to study the role of CXCR-1/2 neutrophil surface receptors and neutrophil 
phenotype in the progression of sepsis. This model was used for in silico evaluation of an 
extracorporeal treatment that modulates these surface receptors. This information helps support 
the underlying mechanism of the NeRD and guide intervention timing. Findings from development 
of the NeRD device were also be used to establish future directions of extracorporeal devices for 
treatment of sepsis. In particular, approaches that modulate neutrophil activity within an 
extracorporeal circuit were explored. The final element of this dissertation focusses on 
implementation of zwitterionic macromolecule conjugation to functionalized polymethylpentene 
(PMP) hollow fiber membranes. Different fiber functionalization configurations, including amine 
and hydroxyl fiber functionalization were evaluated. Macromolecular coatings may be integrated 
into the NeRD to improve device hemocompatibility at a later stage of development. 
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2.0  BACKGROUND 
2.1 SEPSIS 
The incidence of sepsis is expected to increase over the next 10-20 years as the population ages 
[1]. Despite improvements in care, the hospital mortality rate associated with sepsis has remained 
persistently high and is nearly 20% [1,5,6]. Recent studies have shown that at one year, survival 
is less than 60% for patients with septic shock [7]. Sepsis is now the leading cause of in-hospital 
death in the United States [1,8], yet there are currently no FDA approved specific treatments for 
sepsis. Intensivists are limited to managing the symptoms of sepsis until the patient’s immune 
system naturally recovers, if it does so. The current standard of care for sepsis is treatment of the 
causal infection with source control and antibiotics, while providing necessary organ support using 
drugs (e.g. vasoactive medication) or devices (e.g. hemodialysis, mechanical ventilation, etc.) [9]. 
2.1.1 Clinical definition 
There has been much debate about how to define sepsis, leading to inconsistency amongst reported 
results and treatments prior to the early 1990s. The wide range of symptoms and presentations of 
sepsis makes it particularly challenging to identify and define. To help address this challenge, the 
first consensus definition of sepsis was established as a systemic inflammatory response to an 
infection. Additionally, severe sepsis was defined as sepsis with complications related to organ 
dysfunction and septic shock was identified as sepsis with symptoms associated with hypotension 
[10]. Additional clarity was added during the surviving sepsis campaign [5,11], which defined 
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sepsis and established guidelines for treatment. A clear diagnostic criteria was established, which 
included infection, general variables such as temperature and heart rate, inflammatory variables 
such has white blood cell count, hemodynamic variables, organ dysfunction observations, and 
tissue perfusion variables (see Table 1). Additionally, severe sepsis was defined as sepsis with 
sepsis induced hypoperfusion or organ dysfunction. These new standards improved consistency. 
 
Table 1. Diagnostic criteria for sepsis. Adapted from Dellinger, et al[11]. 
Suspected or documented infection and some of the following: 
General Inflammatory Hemodynamic Organ-dysfunction Tissue-perfusion 
Fever Leukocytosis Arterial 
hypotension 
Arterial hypoxemia Hyperlactatemia 
Hypothermia Leukopenia   Acute oliguria Decreased 
capillary refill 
Elevated heart 
rate 
>10% immature 
WBC 
 
Creatinine increase 
 
Tachypnea Elevated plasma C-
reactive protein 
 
Coagulation 
abnormalities 
 
Altered mental 
status 
Elevated 
procalcitonin 
 
Ileus 
 
Significant 
edema 
  
Thrombocytopenia 
 
Hyperglycemia 
 
  Hyperbilirubinemia 
 
2.1.2 Contributions of innate and adaptive immunity to sepsis progression 
Many theories have been presented to help understand the progression and root cause of sepsis. 
Early hypotheses were based on the presence of an infection in the bloodstream. Researchers 
determined that infection alone could not be solely responsible for sepsis, because use of 
antibiotics did not eliminate symptoms. In last thirty years, as our understanding of host immunity 
expanded, it became clear that the patient’s immune response was key to the progression of sepsis. 
Initially, innate immune response was determined to play a key role. Particularly elevated levels 
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of both pro and anti-inflammatory cytokines which were observed in circulation of septic patients 
[12,13]. These cytokines led to an overwhelming immune response, leading neutrophil activation 
and organ dysfunction. If the patient survives the hyperinflammatory phase of sepsis, a strong anti-
inflammatory response will follow. This is a result of the anti-inflammatory cytokines which were 
released in parallel and response to pro-inflammatory cytokines. This response leads to immune 
suppression and inability of the patient to fight the underlying or additional infections. 
 
 
Figure 2. Possible sepsis progressions. Patients can die from either overwhelming inflammation, sustained 
inflammation, or immunosuppression. Adapted from Hotchkiss, et al [14]. 
 
More recently, the host-response hypothesis has been expanded to also include the role of 
adaptive immunity. This is particularly relevant in the development of the anti-inflammatory 
response [14,15]. This concept does not ignore the importance of innate immunity, but presents 
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the possibility of targeting adaptive immune processes to minimize immune dysfunction, 
particularly for patients who survive the initial hyperinflammatory stage. These hypothesis are 
shown in Figure 2. This also highlights the importance of establishing immune homeostasis to 
encourage patient’s recovery. Treatments which alter immune response to drastically are likely to 
lead to patient morbidity and mortality. The importance of treatment timing is also critical, as 
immune response is clearly time dependent and perturbations to either innate or adaptive immunity 
may only be possible at a single stage of sepsis development. 
2.1.3 Role of neutrophils in the progression of sepsis 
Neutrophils are the first responders to sites of inflammation and play critical roles in the innate 
immune response. Neutrophils are short lived (less than a week) granulocytes, which are the most 
common type of white blood cell. They typically enter the blood stream as mature cells, without 
the ability to proliferate [16]. Cytokine signals prime and active neutrophils [17–19], stimulating 
extravasation. Neutrophils migrate through the endothelial cell wall, following chemokine 
gradients to the source of infection. At the site of infection neutrophils are able to help eliminate 
pathogens through granule production, phagocytosis, and generation of neutrophil extracellular 
traps (NETs) [20–22]. Additionally, neutrophils can release cytokines, leading to continued 
inflammation and leukocyte infiltration. Recent studies have also linked neutrophils to adaptive 
immune functions, increasing the importance of their role in the later hypoinflammatory stage of 
sepsis [23,24]. While neutrophils are critical to eliminating infections, they are a double edged 
sword, capable of damaging healthy tissue [25]. The same mechanisms used to eliminate pathogen 
will just as easily damage healthy tissue.  
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Normally, neutrophils migrate from the bloodstream into the infected tissues due to 
inflammation there by sensing chemical gradients of the chemokine IL-8, which is released by 
macrophages in response to foreign invaders like bacteria. The IL-8 chemokine binds to the 
expressed neutrophil cell surface receptors CXCR-1 and CXCR-2 and induces chemotaxis to the 
site of infection [2]. The increased neutrophil activity in sepsis, however, results in undesirable 
systemic-level inflammation and elevated IL-8 levels in healthy tissues and organs [26,27]. 
Activated neutrophils then infiltrate these tissues/organs where they can damage cells and lead to 
multiple organ dysfunction [2,28]. This process is illustrated in Figure 3. The lung is especially 
susceptible to sepsis induced organ failure. Again, potential treatments that indiscriminately 
suppress the activity of neutrophils can cause immune suppression and the inability to clear the 
causal infection [15,29,30]. 
 
 
Figure 3. Neutrophil induced organ damage occurs when cytokines enter systemic circulation. 
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2.1.4 Current treatments 
There is a long history of potential treatments targeting sepsis. While many approaches have shown 
promise early in development, no specific treatments have been FDA approved [31]. The lack of 
substantial advancements comes even with advancements in understanding the underlying 
pathogenesis of sepsis. This lack of progression highlights the complexity and challenges of sepsis 
treatment. The current standard of care is management of symptoms, source control, and 
supportive care. Although new treatments have not been reaching patients, recent clinical studies 
have shown a gradual improvement in mortality among patients suffering sepsis, with current 60 
day mortality sitting at approximately 18% [6,7]. 
2.1.4.1 Protocolized treatment and supportive care 
Physicians have long been searching for ways to improve outcomes for patients suffering from 
sepsis. One previously promising approach, called early goal-directed therapy (EGDT) [32] 
followed a 6-hour protocol which quickly and aggressively used central venous catheterization 
intravenous fluids, vasopressors, blood transfusions, and dobutamine to meet target physiologic 
parameters. Initial single-center clinical trials indicated this approach provided a significant 
improvement in short term mortality of patients. These studies encouraged physicians to move 
towards protocolized treatments, but there were arguments over which elements of the protocol 
were responsible for improvements in mortality (or whether the outcomes could be repeated in a 
large scale clinical study) [33,34].  
In 2014 a multicenter clinical study (the ProCESS trial), was completed which specifically 
set out to address this question. Protocol based resuscitation was compared to both usual care and  
an EGDT based protocol which used central hemodynamic monitoring to guide treatments [7]. 
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This study found that protocol-based resuscitation on septic shock patients diagnosed in the 
emergency department did not improve outcomes based on usual care. These show that required 
central hemodynamic monitoring is not critical to reducing mortality in septic patients. 
Additionally, the lack of difference between mortality in treatment groups may be because 
physicians had already adjusted their treatment approach to reflect the advantages of EGDT, with 
a focus on early diagnosis and treatment.  
Currently the focus of sepsis management is early diagnosis, source control, and treatment 
of symptoms. These steps have been shown to improve patient outcomes [35] Initial treatment 
guidelines are to be completed within 6 hours of sepsis presentation. These are intended to provide 
cardiorespiratory resuscitation and address the underlying infection. Use of intravenous fluids, 
vasopressors, and respiratory support are suggested when necessary. After being transferred to the 
ICU patients begin a new set of therapies which focus on organ function and de-escalation of 
treatment. While these treatment guidelines have gradually improved patient outcomes, there is 
still a need for therapies that address the underlying mechanisms of sepsis and provide physicians 
with more treatment options. 
2.1.4.2 Pharmaceuticals 
Many experimental pharmaceutical treatments have been tested in animals and early stage human 
clinical trials. However, currently none of these treatments are FDA approved specifically for use 
in sepsis. Many of these treatments target the inflammatory response, attempting to suppress the 
hyper immune response and associated organ damage. The only immunosuppressive treatment 
currently recommended for certain patients is a short low dose of hydrocortisone [11,36], but even 
this is controversial due to the possibility of unintended immune suppression and other 
complications. 
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Activated protein C (APC) therapy showed promise early in its development. This therapy 
is intended to limit coagulation complications observed during sepsis. During sepsis endothelial 
cell expression of thrombomodulin is typically impaired, limiting APC generation from circulating 
protein C. Administration of APC is thought to facilitate controlled fibrinolysis and inactivation 
of factor Va and VIIa, limiting coagulation complications [37]. Additionally, APC is thought to 
modulate the inflammatory response in sepsis, inhibiting IL-1, IL-6, and TNF-α production [38]. 
Initially trials with recombinant APC indicated an improvement in mortality [39] and the drug 
gained FDA approval. However, these clinical results could not be replicated [40] and FDA 
approval was withdrawn and the drug was removed from all markets due to lack of clinical 
evidence and possibility of severe complications. 
Pharmaceuticals have also directly targeted inflammatory response to encourage either pro 
or anti-inflammatory responses. Experimental drug therapies to attenuate pro-inflammatory 
cytokines such as tumor necrosis factor (TNF) and interleukin-1 (IL-1) have had little success [4]. 
Use of interferon-γ and GM-CSF have attempted to stimulate immune response in 
immunosuppressed patient, but clinical results have been mixed [41–43]. While these might have 
potential benefits for certain patients, clinical data does not appear to support their widespread use.  
Other pharmaceutical treatments target elements of sepsis ranging from coagulation to 
immune response. High-mobility group box 1 (HMBG1) has been targeted for therapy in sepsis. 
Studies have shown that HMGB1 plays a key role in sepsis progression and inflammation [44–
47]. However, these studies have not progressed beyond pre-clinical testing and full therapeutic 
implications are not understood.  
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2.1.4.3 Blood filtration 
Extracorporeal devices addressing sepsis have primarily focused on removing components from 
whole blood. Specifically, they target cytokines or endotoxin and pathogens, intending to disrupt 
the progression of sepsis. These device, which include hemofiltration and hemoadsorption, broadly 
modulate cytokine levels [48,49]. It is hypothesized that widespread removal of cytokines will be 
beneficial in two ways. First, broad removal of cytokines will dampen both pro and anti-
inflammatory immune response, allowing the patient to return to homeostasis [50]. Second, it is 
believed that cytokine removal from blood may decrease cytokine concentrations in tissue by 
changing the concentration gradient, potentially reducing organ damage [51]. However, clinical 
results have not yet supported the widespread use of blood filtration. These techniques are more 
commonly utilized in Japan than the United States and Europe [52]. Further clinical testing may 
determine which subset of patients would benefit from use of these devices. 
Cytokine removal from whole blood is typically completed using either hemofiltration or 
hemoadsorption. Hemofiltration utilizes semi-permeable membranes to remove components of a 
specific size range from blood. Pore size on these membranes prevent large solutes such as albumin 
from being removed, but can remove smaller cytokines. High volume hemofiltration (HVHF) is a 
potential approach to quickly remove a substantial amount of cytokines from plasma. High flow 
rates and convective transfer lead to faster removal than relying on diffusion alone. Use of HVHF 
has shown encouraging results in animal studies and smaller clinical studies [53–55], particularly 
regarding improvement of hemodynamic parameters. However, additional large studies are likely 
required to achieve widespread use. Other lower flow hemofiltration techniques, such as 
continuous renal replacement therapy and conventional continuous venovenous hemofiltration, 
have not shown advantages compared to standard care for septic patients [56,57]. High cutoff 
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membranes (HCO) have increased pore size, allowing more efficient removal of a wider range of 
cytokines [58]. The downside of this increased pore size is increased albumin loss. Hemodialysis 
using HCO relies on diffusion to remove solutes and appears to allow for greater removal of 
cytokines while minimizing albumin loss [59,60].    
Hemoadsorption removes components from blood using a sorbent surface which comes in 
direct contact with blood in an extracorporeal circuit. Unlike hemofiltration there are no limitations 
on target molecule size. Additionally, certain solutes can be removed preferentially by carefully 
selecting sorbent properties such charge, hydrophobicity, and chemical composition. Polymyxin 
B, which is approved for use in Japan, is an example of a hemoadsorption device which 
preferentially removes endotoxin from the blood [61,62]. Recently, a multi-center clinical study 
examining use of Polymyxin B outside of Japan concluded that there are some benefits associated 
with endotoxin removal [63]. However, there is some argument over the relevance of these results, 
and a data from US and Canadian patients did not appear to meet its primary endpoint [64]. While 
some results and case studies have been encouraging, it is clear more research is required to 
improve device deployment. 
The Cytosorb filter has been approved in the European Union for extracorporeal cytokine 
removal. Porous polymer beads are used to specifically remove hydrophobic middle molecular 
weight proteins such as cytokines. This approach leads to rapid removal of multiple cytokines 
associated with negative outcomes in sepsis [65]. This approach has showed success in animal 
models and case studies [49,66,67], but larger clinical studies have either not been completed or 
have not shown significant reductions in pro-inflammatory response [68]. Coupled plasma 
filtration adsorption works in a similar manner to the Cytosorb filter, but plasma is separated from 
whole blood prior to cytokine removal. Removing the cytokines from plasma minimizes 
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complications related to coagulation, platelet activation, and red blood cell damage. Clinical data 
is still lacking, but this approach appears to be fairly safe and has shown the ability to remove 
cytokines from circulation [69–72]. Like many therapies that target the immune response in sepsis, 
early treatment may be required to obtain benefits from this approach. High-adsorption 
hemofiltration  combines hemofiltration and hemoadsorption to effectively remove endotoxin 
and/or cytokines [54,73]. 
Many blood filtration therapies are challenged by their tendency to remove antibiotics from 
circulation in addition to targeted solutes. Antibiotics play a critical role in the treatment of sepsis 
and it is important for clinicians to understand how antibiotic regimens must change with use of 
these devices. An early stage technology being developed at the Wyss Institute is constructed from 
modified hemodialysis fibers coated with genetically modified form of the human opsonin 
Mannose Binding Lectin linked to an Fc domain [74]. This coating efficiently removes a range of 
pathogens and endotoxin. Additionally, research in rats has shown a synergistic effect when this 
treatment is combined with antibiotics, due to the device’s ability to adsorb pathogen-associated 
molecular patterns released after antibiotic treatment. This technology is still extremely early 
stage, but shows some promise of extracorporeal devices in treatment of sepsis. 
 Another approach, being developed by David Humes at University of Michigan, directly 
targets activated neutrophils that cause organ damage. The Cytopherx device utilized a selective 
cytopheretic device, which binds activated neutrophils within an extracorporeal circuit [75]. Pre-
clinical studies have shown promise using this approach for sepsis and other inflammatory diseases 
[76,77]. A small clinical study using the Cytopherx device on patients suffering from acute kidney 
injury showed no, significant difference in 60 day mortality, but there were issues with maintain 
correct levels of calcium in the circuit, limiting he devices efficacy. There was some potential 
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improvement when only patients who were within recommended protocol parameters were 
considered [78]. This study illustrated challenges of implementing a device which relies on citrate 
anticoagulation, which is not widely used and requires a well trained staff. Another downside of 
this approach is removal of activated neutrophils from circulation, potentially limiting the patient’s 
ability to fight the underlying infection. However, with further data and clinical training to take 
full advantage of the device’s ability to modulate neutrophil activity, this approach may prove 
beneficial? Additionally, this device shows that there is promise in targeting neutrophil’s role in 
sepsis and other acute inflammatory conditions. 
Overall, extracorporeal devices have made much progress in sepsis treatment over the last 
decade, with many options showing promise. However, none of these approaches have established 
sufficient clinical data to be utilized worldwide, limiting their impact. While more clinical data 
may open the doors for increased usage, sepsis treatments in general must adjust target clinical 
endpoints and better select target patients. While a theranostic approach did not appear effective 
in Spectral Diagnostics North American Polymyxin B trial, improved patient diagnostics may help 
limit patient heterogeneity and improve device deployment. This may be particularly critical for 
therapies that are time sensitive such as immunomodulatory treatments. For these therapies late 
deployment may prove to be ineffective or even detrimental. An important takeaway from the 
plethora of experimental extracorporeal treatments is their improving safety. Typically 
complications related to extracorporeal devices have been limited, showing that an extracorporeal 
devices are a safe approach which physicians are likely to be comfortable using. 
 16 
3.0  COMPUTATIONAL MODELING OF CXCR-1/2 SURFACE RECEPTORS, 
NEUTROPHIL PHENOTYPE, AND EXTRACORPOREAL TREATMENTS WHICH 
MODULATE THESE FACTORS IN THE PROGRESSION OF SEPSIS 
The following chapter includes work from the manuscript titled A Neutrophil Phenotype Model 
for Extracorporeal Treatment of Sepsis [79], which was published in PLOS Computational 
Biology. 
While understanding of the underlying mechanisms in sepsis has been rapidly improving, 
translation to clinically effective  treatments has proven very challenging [9,80]. Much of this 
difficulty translating treatments may be due to the diversity and complexity of individual immune 
response and patient population [81,82]. These complexities lend themselves well to 
computational modeling, which can help integrate these complexities into a unified 
pathophysiological framework and optimize potential treatments [83]. This chapter discuss the 
construction of a computational model used to predict neutrophil induced organ damage in sepsis 
then estimate efficacy of a proof of concept extracorporeal device which modulates CXCR-1/2 
activation. These results are used to support device proof of concept and better understand how to 
deploy device clinical use. 
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3.1 INTRODUCTION 
Sepsis, a systemic inflammatory response due to an infection, affects 900,000 Americans per year 
and its incidence is expected to increase over the next 10-20 years as the population ages [84]. 
While it is acknowledged that sepsis is a growing problem, its associated mortality rate has 
remained persistently high for the last 20 years and is currently near 20% [84–87]. Sepsis is now 
the leading cause of in-hospital death in the United States, yet there are no FDA approved specific 
treatments [88]. While understanding of the underlying mechanisms in sepsis has been rapidly 
improving, translation to clinically effective  treatments has proven very challenging [89,90]. 
Much of this difficulty translating treatments may be the diversity and complexity of individual 
immune response and patient population [91,92]. These complexities lend themselves well to 
computational modeling, which can help integrate these complexities into a unified 
pathophysiological framework and optimize potential treatments [83]. 
Neutrophils are one of the first responders to sites of inflammation and play a critical role 
in the innate immune response. When effective, neutrophils migrate from the bloodstream through 
endothelial walls to the site of inflammation by sensing gradients of chemokines, which bind to 
neutrophil cell surface receptors. In early stages of sepsis neutrophils potentially play a duplicitous 
role, both actively fighting the invading pathogen but also contributing to undesirable systemic 
inflammation, which often leads to multiple organ dysfunction, immune paralysis, or death 
[20,93]. Neutrophils’ roles in sepsis are well recognized but the dynamics of multiple phenotypes 
and their impact on treatments is not fully understood. A key chemokine impacting neutrophil 
behavior and phenotype is interleukin-8 (IL-8). IL-8 signals through functionally distinct surface 
receptors CXCR-1/2, which are primarily expressed on neutrophils. CXCR-1 is primarily 
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responsible for activating phospholipase D [94], which mediates respiratory burst and other 
pathogen killing functions. CXCR-2 has been shown to stimulate migratory functions such as 
chemotaxis and diapedesis [95,96]. 
 The motivation of this work is to use computational modeling of CXCR-1/2 signaling, and 
the associated dynamics in neutrophil phenotype composition, to explore whether modifying this 
dynamic could be exploited to favorably impact outcome in sepsis. A population based 
mechanistic computational model, which incorporates both receptor level dynamics and neutrophil 
response to pathogen, was developed to explore the mechanisms involved in sepsis progression 
and calibrated in septic baboons. Furthermore, an experimental extracorporeal treatment which 
modulates CXCR-1/2 receptor levels was evaluated in silico using the model framework. The 
computational model described in this manuscript provides a physiologic rationale for neutrophil’s 
CXCR-1/2 mediated activity in sepsis, delivers insight into the overriding mechanisms involved, 
and suggests that interventions aiming to modulate phenotypic composition are time sensitive. 
3.2 METHODS 
3.2.1 Experimental Data Set Protocol 
After general anesthesia, instrumentation and a 30 minute stabilization period, sixteen 
baboons (Papio ursinus) weighing between 19 and 32 kg were infused with 2 x 109 CFU 
Escherichia coli per kg over a two-hour period as described previously [97]. Thereafter, antibiotic 
therapy was delivered (gentamycin 4mg/kg twice a day).  Eight animals were placed in an acute 
study lasting 6 days, while another eight were placed in the chronic study intended to last 28 days. 
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All animals were observed for a 4-hour period after bacteria infusion then 11, 23, 35, 47, 72 hour 
and 6 days after infusion. Pathogen counts in blood, IL-8, creatinine, white blood cell, neutrophil 
elastase / α1-PI complex, and other physiologic parameters and biomarkers were gathered at 
multiple time point. For animals in the chronic study an additional time point was collected at 28 
days. At the end of the study period, the baboons were again anesthetized for measurements and 
thereafter sacrificed with an overdose of pentobarbital. This study was approved by the 
Institutional Animal Care and Use Committee at Biocon Research Institute and animals were 
treated according to NIH guidelines. 
3.2.2 Model Framework and Description 
A simplified mechanistic model of IL-8 mediated activation of CXCR-1/2 receptors and neutrophil 
response to a pathogen was developed based on available literature information and general 
knowledge of acute inflammatory response. Receptor level dynamics and systemic parameters 
were coupled with multiple neutrophil phenotypes to generate dynamic populations of activated 
neutrophils which reduce pathogen load, and/or primed neutrophils which cause adverse tissue 
damage when misdirected. Mathematical representation of the interactions detailed in Figure 4 
were generated using ordinary differential equation (ODE) framework with the rate of interactions 
described by mass action kinetics or Hill type kinetics [98,99]. The interactions included in the 
model gives rise to 16 ODE state variables and 43 rate parameters.    
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Figure 4. Model diagram detailing neutrophil phenotypes and critical feedback loops. 
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In brief, the model is initiated by a pathogen load, which represents a bacterial inoculation. 
Presence of pathogen leads to continued growth as well as IL-8 and fMLP cytokine production. 
IL-8 is generated indirectly from pathogen generation from responding phagocytic mononuclear 
cells [100]. IL-8 initiates CXCR-1/2 activation in the receptor level, which in turn generates 
neutrophil phenotype change. Depending on phenotype, neutrophils may cause either pathogen 
elimination or misdirected tissue damage. A systemic damage indicator represents overall patient 
health. Increased systemic damage results in further IL-8 generation [101,102], resulting in a 
positive feedback loop. This simplified system captures the basic functionality of acute IL-8 
mediated immune response to pathogen and is capable providing valuable feedback on potential 
therapeutic treatments modulating these mechanisms. A more detailed description of model 
equations follows. 
Pathogen: Equation (1) describes the population of foreign pathogen. Base pathogen 
growth rate increases linearly with pathogen until approaching a carrying capacity at elevated 
pathogen loads. In addition to basal pathogen death, the Neutrophil kill/migrate phenotype is 
capable of decreasing pathogen population through diapedesis, followed by targeted phagocytosis 
[20,103,104]. 
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Ligands: Interleukin-8 (IL-8) and fMLP: In the model, neutrophils progress through 
multiple phenotypes which dictate neutrophil migratory, phagocytic, and antibiotic activity. The 
association of chemokine IL-8 with the surface CXCR-1/2 triggers the transition of basal 
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neutrophils to functional phenotypes. Previously characterized receptor surface activation, 
internalization, and recycling rates of CXCR-1/2 are utilized to predict receptor levels and 
neutrophil phenotypes in response to systemic IL-8 stimulation [95,105]. IL-8 production rate is a 
function of elevated pathogen and tissue damage [106,107]. Both terms are represented as Hill 
Equations in equation (2). While IL-8 is not directly linked to pathogen levels, this simplified 
representation captures IL-8 release from macrophages and endothelial cells in response to 
infection. 
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Equation (3) characterizes a general pro-inflammatory pathway, which is independent of 
CXCR-1/2 activation has been added to represent alternate means of neutrophil induced pathogen 
activation. This generic pathway is not modeled using receptor level dynamics and directly 
transitions the NBasal (NB) population to NKilling/Migratory (NK/M).The generic proinflammatory ligand 
growth is dictated by pathogen level. 
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Neutrophil Surface Receptors CXCR-1 & CXCR-2: Receptor level dynamics dictate 
neutrophils advancement into one of four phenotypes depending on CXCR-1/2 surface activation. 
Each receptor can occupy one of the three states, namely free surface receptor, surface receptor 
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bound to IL-8 and internalized receptor bound to IL-8 [108]. Equation (4) and Equation (5) 
describe CXCR-1 surface and internalized populations, which have been non-dimensionalized to 
remove the free receptor state. Equivalent equations are present for CXCR-2. The active surface 
state was modeled as the dynamic condition which drives neutrophil population phenotype change 
[109]. This model makes the assumption that CXCR-1/2 receptors are conserved. 
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Neutrophil Phenotype: Equation (6) represents the resting state (NB) represents basal 
neutrophils which have not been stimulated by IL-8 or other proinflammatory stimuli. These 
neutrophils are mobile in blood, but not capable of causing systemic damage or utilizing their anti-
pathogen capacity without transitioning to another phenotype. All neutrophils begin in this basal 
state prior to activation and priming. Without stimulation, neutrophil growth and death rates are in 
equilibrium, however growth rate increases with the introduction of pathogen, which has been 
expressed through a filter equation to produce a physiologic time delay [20,110]. CXCR-1/2 
surface complex levels dictate the transition rates of NB to the NMigratory (NM) or Nkilling (NK) 
phenotypes. Additionally, there is a direct pathway to transition NB to NK/M. This mechanism 
represents a general proinflammatory process independent of CXCR-1/2 signaling. A filter 
equation was generated in Equation (7). This function fits the physiologic delay between pathogen 
generation and increased neutrophils entering circulation. 
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Equation (8) contains neutrophils which have been activated via IL-8 mediated CXCR-2 
stimulation. 
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Equation (9) characterizes the killing phenotype (NK), representing neutrophils which have 
been activated via IL-8 mediated CXCR-1 stimulation. NK neutrophils are capable of untargeted 
cytotoxic activity, resulting in systemic organ damage. The CXCR-1/2 surface population dictates 
transition rates into phenotypes. Neutrophil elastase / α1-PI complex was utilized in the model to 
fit NK neutrophil population. As shown in Equation (10) levels of neutrophil elastase / α1-PI 
complex equate to levels of circulating NK phenotypes. 
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Both NM and NK phenotypes are capable of progressing to the NK/M phenotype through 
CXCR-1/2 surface receptor activation. This neutrophil state (NK/M), shown in Equation (11), 
represents neutrophils which have been activated through both CXCR-1 and CXCR-2 and are 
capable of target pathogen removal, effectively fighting infection. The pathogen equation 
(Equation (1)) contains a term which dictates pathogen death in response to NK/M levels. Once 
activated through CXCR-1/2 neutrophils are not capable of returning to the basal NB phenotype.  
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Damage: A systemic damage indicator (Equation (12)) was developed to represent overall 
animal health. Damage is increased by the population of NK and decays gradually as tissue and 
organs recover. Creatinine, a biomarker for kidney function, was utilized in Equation (13) as an 
indicator for the damage term ensemble computation. Creatinine is maintained at a constant level 
in the absence of damage, but systemic levels increase with damage as body’s ability to clear 
creatinine decreases [111]. 
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The model uses empirical time series of Pathogen (CFU), IL-8 (nM), creatinine (mM), 
White Blood Cell count (103 cells/µl), and neutrophil elastase / α1-PI complex (ng/ml) for 
computation of the ensemble. State variables and their initial conditions are listed in Table 2. 
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Table 2. Initial Conditions. 
No. Symbol Description Initial Condition – 
Survivors 
Initial Condition –
Non-Survivors 
Units 
1 P  Pathogen 1000 1000 CFU 
2 BN  Basal neutrophils 4.4 5.06 103 cells/µl 
3 KN  
Neutrophils with 
killer phenotype 
0.0 0.0 103 cells/µl 
4 MN  
Neutrophils with 
migratory phenotype 
0.0 0.0 103 cells/µl 
5 /K MN  
Neutrophils with dual 
phenotype  
0.0 0.0 103 cells/µl 
6 8ILC  
Systemic IL-8 
concentration 
0.0 0.0 nM 
7 D  Global tissue damage 0.0 0.0 unitless 
8 1R sC  
Surface CXCR1 
population 
0.0 0.0 unitless 
9 1R iC  
Internalized CXCR1 
population 
0.0 0.0 unitless 
10 2R sC  
Surface CXCR2 
population 
0.0 0.0 unitless 
11 2R iC  
Internalized CXCR2 
population 
0.0 0.0 unitless 
12 creatC  Creatinine 91.5455 102.4 nM 
13 F  Filter term 0.0 0.0 unitless 
14 1R tC  CXCR1 trapped 0.0 0.0 unitless 
15 fMLPC   fMLP 0.0 0.0 nM 
16 elasC  
Neutrophil elastase / 
α1-PI complex 
0.0 0.0 ng/ml 
17 WBC  
Total white blood 
cells 
4.4 5.06 103 cells/µl 
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3.2.3 Parameter estimation 
The model contains 38 parameters, 13 of which are fixed based on literature data (Table 
2). Parameter values were inferred using a Bayesian parallel tempering approach [112,113], which 
utilizes traditional Markov Chain Monte Carlo (MCMC) methods to sample the Bayesian posterior 
distribution P(p|y), the probability of parameter set p given data y, given by the Bayes formula 
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where L(y|p) is the likelihood of observing y for a model with parameters p, θ(p) is the prior 
distribution, and  ( | )L Y  p p  is the normalizing constant. Additional sampling efficiency is 
gained by running multiple parallel chains evolving at different temperatures. Higher 
temperature increases the likelihood of acceptance of proposed steps. This allows the high 
temperature chains to move more freely through the parameter space, avoiding getting stuck in 
local minima. This results in more efficient exploration of parameter space [114,115] a method 
we have applied extensively in parameter estimation of practically unidentifiable complex non-
linear models [83,116,117]. This resulted in the creation of parameter ensembles, where each 
parameter is represented by a posterior distribution, rather than a single value. Free parameters 
were fit separately to the survivor and non-survivor experimental data sets, resulting in two 
parameter ensembles representing surviving and non-surviving animals. 
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3.2.3.1 Bayesian Priors 
Prior distributions were selected for each parameter. In each case uniform priors were used, with 
a suitably large range so as to encompass all reasonable parameter values. This was ideal due to 
the limited prior knowledge and phenomenological nature of many of the parameters. Tighter 
ranges were enforced on select parameters as required to avoid non-physiologic model behavior. 
All candidate parameter values were selected from these pre-defined priors. 
3.2.3.2 Parameter Set Fitness 
Fitness (log likelihood) of candidate parameters sets was determined by the difference between 
model simulations and experimental data, as determined by the sum of squared residuals cost 
function,  
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Where i, j,kw  is a weighting function, i, j,ky  is the output for a simulation with a single set of 
parameters, i, j,kyˆ  is the experimental mean, and i, j,kσ  σi,j,k is the experimental standard 
deviation at time point i, observable j, and data set k. No additional penalties or constraints were 
added to parameter selection. To ensure proper fitting of the pathogen observable a threshold 
was added to change all values below the experimental limit of detection (4.4 CFU) to 0. 
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3.2.3.3 Parallel tempering 
To efficiently sample the posterior distribution, six separate Markov chains were run, initiated 
with parameter values randomly selected from the supplied prior distributions which met a 
maximum energy criterion. Each chain was initiated with a temperature and step size parameter 
which controlled the chain’s ability to fully explore the parameters space. Chains were allowed 
to swap from a higher temperature to a lower temperature every 25 steps to allow for local 
sampling of newly found local minima. Step size and temperature parameters dynamically 
changed every 6,250 and 2,500 steps respectively to attempt to reach an ideal step acceptance 
rate of 23% [118], and swap rates of 15%-30%. Once these targets were reached, the temperature 
schedule and step sizes were fixed. Parameter sets were saved every 25 steps. Full exploration of 
parameter space was confirmed by examining, for each parameter, the frequency histogram of its 
full marginal posterior distribution, confirming that it spanned the prior domain. 
We measured convergence and chain stationarity using the Gelman-Rubin criteria [119,120]. All 
parameters had converged with a potential scale reduction factor (PSRF) < 1.1 following 
200,000 (x25) MCMC steps. Another 100,000 steps were taken to build a posterior distribution 
for each parameter that would be used for all model analysis and simulation. This ensured that all 
samples from the burn-in time for each chain were discarded, and only samples from the correct 
stationary distribution were used. The ensemble of all parameter sets from the lowest chain 
comprised the computed ensemble (posterior distribution). 
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3.2.4 Selection of key parameters 
In order to better capture the underlying biological differences between animals that survive and 
those that die following the same challenge we attempted to identify the most important 
parameters in determining animal fate. After computing ensembles for survivors and non-
survivors, we performed regularized logistic regression, forward conditional stepwise logistic 
regression, and backward conditional logistic regression to identify a subset of parameters that 
are most indicative of outcome.  Predictors consisted of all estimated parameters of both 
ensembles, and the indicator variable was the source (survivor or non-survivor) of the ensemble. 
Parameters were selected that were considered significant by all three methods, leaving a set of 
seven key parameters. 
3.2.5 Model fitting 
A second round of model fitting was then performed. In this round, 18 of the 25 parameters were 
fit simultaneously to both data sets, resulting in identical parameter values in the two ensembles. 
The seven parameters identified as being significant were fit twice, once against the survivor 
data set and once against the non-survivor data set, resulting in different parameter values across 
the two ensembles. This resulted in a smaller and more focused difference between the final 
ensembles. 
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3.2.6 Global sensitivity analysis 
Global Sensitivity analysis was done to determine the independent and correlated contributions 
of rate parameters on cumulative damage. Area under the damage curve was chosen as the 
system output. To reduce the computational cost of GSA, Random Sampling High Dimensional 
Model Representation (RS-HDMR) approach was used [121]. Here, a multivariate output 
function (eg. AUCD) was approximately represented by weighted optimal expansion functions 
(called as component functions). The expansion coefficients of these functions were determined 
by least-squares regression simultaneously from one set of Monte Carlo samples. In general, for 
input vector, x = [x1, x2, ..., xn ] of rate parameters, in an n–dimensional space, a multivariate 
output function, f (x ), is approximated by a sum of terms including the mean ( f0) and the 
component functions (gl ). Mathematically, 
f (x ) = f0 + gl
l=1
2n-1
å  
Here, the index l  indicates all possible combinations of the input parameters. In practice, not all 
component functions are significant and an F-test can be used to determine which component 
function should be excluded from the expansion [122]. For our work, we evaluated the variance 
based Sobol’ indices using these component functions. The workflow adopted here starts with 
generation of Monte Carlo samples of the rate parameters from the ensembles obtained by the 
parallel tempering approach. Since they come from the ensemble, information on the covariance 
between the parameter distributions for the population of survivors and non-survivors is retained. 
Next, a detailed procedure is followed which includes simultaneous construction of all the 
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component functions, removal of non-significant component functions using an F-test ratio 
score, re-evaluation of component functions and finally evaluation of the Sobol’ sensitivity 
indices. The first order Sobol’ sensitivity indices which capture the influence of a single 
parameter (but averaged over the other parameters) are defined as: 
Sl =
Cov( f (x ),gl (x ))
s 2
,  l =1, 2, 3,...., n  
Here, s 2 is the total variance in the output and Cov(·) is the covariance between the output 
function and each of the first order component functions. For clarity, the component function, gl
, is written as a function of x  but in reality it is only a function of the input parameter for which 
it is defined (for example, xl ) and not the entire vector. Further, this sensitivity index is a sum of 
two terms that capture independent (S al ) and correlated contributions (S
b
l ) of the input, which are 
defined as: 
Sal =
gl (x ),gl (x )
s 2
 and 
Sbl =
gl (x ),gk (x )
k=1
k¹l
n
å
s 2
. The inner products, · , are defined as: 
gk (x ),gl (x ) = ... w(x )gk (x )gl (x )dx1
xn
ò
x1
ò ...dxn  and w(x ) is the probability density 
function of the inputs informed by the parameter ensembles. Similar equations can be written for 
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the higher order component functions and sensitivity indices. Further details on the evaluation of 
the component function for various types of models are given in [121,123,124]. To determine the 
importance of a given parameter, it is necessary to combine all the important sensitivity indices 
(all orders) into a total sensitivity index, which for a parameter i  can be defined as: 
STi = Si + Sij
j=1
j¹i
n
å + Sijk
j<k=1
j,k¹i
n
å +..... .  
For most systems, very high order interactions are negligible and therefore, indices until the third 
order are sufficient, with most systems requiring only until the second order terms [121]. In this 
work, we constructed a third order RS-HDMR. All GSA computations were performed using the 
ExploreHD software (Aerodyne Research Inc., MA, USA). 
3.2.7 Treatment framework 
3.2.7.1 Treatment implementation 
After model fitting and analysis, a potential extracorporeal treatment was introduced (See 
Figure 5). The extracorporeal treatment directly modulates CXCR-1/2 levels of circulating 
neutrophils, limiting passage of NB to NK and NM. This mechanism of limiting CXCR-1/2 surface 
levels is modeled solely in the receptor level equations of the model.  
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Figure 5. Model diagram showing receptor level treatment implementation. 
 
A heaviside function is used to turn treatment on and off at various treatment times. The 
𝑘𝑓𝑡1 parameter represents treatment effectiveness, which combines device size, efficacy, 
efficiency, and flow rate. Equation (14) is the modified CXCR-1 surface receptor equation which 
includes the Heaviside function. Equation (15) characterizes the trapped receptor state of CXCR-
1. Similarly Equation (16) and Equation (17) are constructed for CXCR-2 and its associated 
trapped receptor state. 
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    R1t treat on treat off ft1 R1s R1i R1t ft1' R1t
dC
Heaviside t,k ,k k 1 C C C k C
dt
        (15) 
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    R2t treat on treat off ft2 R2s R2i R2t ft2' R2t
dC
Heaviside t,k ,k k 1 C C C k C
dt
        (17) 
3.2.7.2 Classification of Patient Outcome 
In order to implement and evaluate treatment frameworks, simulated patient survivorship needed 
to be explicitly labeled. This was accomplished using a logistic regression classifier as specified 
by the machine learning software Weka [125]. The estimated parameter ensemble was 
partitioned into a training set and test set to build the classifier, using 20% of the ensemble as 
training data. Two features were used for training, total accumulated damage measured by area 
under the curve of the damage time course for each patient, as well as the peak damage 
experienced by the patient. Training with these features resulted in a classifier that could label a 
patient as surviving or dying after being exposed to a specific infection and possible treatment. 
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3.3 RESULTS 
3.3.1 Computation of parameter ensembles explaining survivor and non-survivor 
dynamics 
Of the 16 baboons subjected to bacterial infusion, 11 (69%) died and 5 (31%) survived, with 
death occurring within 6 days of bacterial. Based on these two systemic outcomes, a thorough 
investigation of the model (see Methods section & Figure 4) was completed to identify parameter 
regimes that explain the dynamics of each group of the responders. 
The initial conditions for the state variables of the ODE were fixed to simulate 
experimental stimulation (Table 2). Among the rate parameters, some were fixed to literature 
values. These included pathogen growth and decay rates, basal decay rates of naïve neutrophils, 
CXCR-1/2 internalization and recycling rates and creatinine decay rate (See fixed parameters in 
Table 3 and Table 4). Remaining parameters were estimated by generating parameter ensembles 
using a Bayesian parallel tempering approach that fit our model to the survivor and non-survivor 
experimental data sets (see Methods). We conducted the parameter estimation process in two 
rounds. In round one, the model was fitted to the two data sets separately. By fitting to the two 
data sets separately, we were able to effectively show that the model was capable of replicating 
both lethal and non-lethal outcomes through only a change in few parameters. In an attempt to 
classify the underlying differences, we identified the parameters that were most influential in 
determining the outcome (survivor or non-survivor) of an individual using stepwise logistic 
regression. This resulted in a list of seven key parameters. These parameters tend to control the 
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rate at which neutrophils grow and how quickly they can change phenotypes, which play a critical 
role in determining how quickly and severely the animal will respond to the infection.  
 
Table 3. Shared Parameter Values 
N
o. 
Symbol Description 
Fixed/
Fitted 
Mean Std. Dev. Units 
1 PGk  Pathogen growth Fixed 1 0 Hour
-1 
2 
/K MPG N
k   
Neutrophil induced 
pathogen death 
Fitted 145.5391 0.040553 
(Hour *103 
cells/µl)-1 
3 PLk  
Pathogen population 
limit 
Fitted 1.6533E-7 2.3409E-7 (Hour*CFU)-2 
4 Pk  Pathogen decay Fitted 271.9904 352.4858 CFU/Hour 
5 
d
pk  Pathogen decay Fixed 1000 0 CFU 
6 
BN
k  
Basal neutrophil 
natural 
Fixed 0.1 0 Hour-1 
7 
KN
k  Killer neutrophil decay Fitted 0.0330 0.0275 Hour-1 
8 
MN
k  
Migratory neutrophil 
decay 
Fitted 0.1244 0.1936 Hour-1 
9 
/K MN
k  
Migratory-Killer 
neutrophil decay 
Fitted 0.1176 0.1772 Hour-1 
1
0 
8M KN N IL
k  
 
IL-8 induced migratory 
neutrophil to 
neutrophil migratory-
killer transition 
Fitted 168.7708 260.7247 Hour-1 
1
1 8IL P
k   
Pathogen induced IL-8 
production 
Fitted 2.7810E-6 2.0441E-6 Hour-1 
1
2 8IL D
k   
Tissue damage induced 
IL-8 production 
Fitted 5.7938E-9 7.9615E-9 nM*Hour-1 
1
3 8IL
k  IL-8 decay Fitted 0.3352 0.0261 Hour-1 
1
4 KD N
k   
Tissue damage induced 
by killer neutrophils 
Fitted 0.0319 0.0285 
(Hour *103 
cells/µl)-1 
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Table 3 (continued) 
1
5 
Dk  Damage recovery rate Fitted 7.0147 8.8870 Hour
-1 
1
6 _filter on
k  Filter production rate Fitted 6.1698E-4 8.2047E-4 (CFU*Hour)-1 
1
7 
1rk  
Dissociation constant 
for R1 receptors 
Fixed 79.2 0 Hour-1 
1
8 
2rk  
Dissociation constant 
for R2 receptors 
Fixed 79.2 0 Hour-1 
1
9 
Dk  
Affinity constant for 
IL-8 to the receptors 
Fixed 2.5E-3 0 Hour-1 
2
0 1i
k  
Internalization rate for 
IL-8-R1 complex 
Fixed 5.196 0 Hour-1 
2
1 
'1i
k  Recycle rate for R1 Fixed 0.612 0 Hour-1 
2
2 2i
k  
Internalization rate for 
IL-8-R2 complex 
Fixed 20.796 0 Hour-1 
2
3 
'2i
k  Recycle rate for R2 Fixed 0.144 0 Hour-1 
2
4 fMLP
k  
Pathogen induced 
fMLP production 
Fitted 5.9866E-7 1.3864E-6 nM*Hour-1 
2
5 
d
fMLPk  
Pathogen induced 
fMLP production 
Fitted 622.9280 1.6952E3 CFU 
2
6 fMLP D
k   
Pathogen induced 
fMLP decay 
Fitted 9.8425E4 1.7303E5 Hour-1 
2
7 B
fMLP Nk   
fMLP induced basal 
neutrophil to 
migratory-killer 
phenotype transition 
Fitted 0.0021 0.0025 Hour-1 
2
8 ne
k  
Scaling of Nk cells to 
neutrophil elastase / 
α1-PI complex levels 
Fitted 0.0351 0.0209 ng/cell 
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Table 4. Unique Parameter Values. 
o. Symbol Description 
Fixed/ 
Fitted 
Mean - 
Survivor 
Std. Dev. 
–survivor 
Mean – 
Non-
survivor 
Std. Dev. 
– Non-
survivor 
Units 
1 
NGk  
Neutrophil baseline 
growth rate, based on 
12 h life 
Fixed 0.506 0 0.54417 0 
103 cells/ 
(µl *Hour) 
2 
creatk  Creatinine decay rate Fixed 0.1591 0 0.1792 0 Hour
-1 
3 
BN G
k   
Pathogen influenced 
neutrophil growth 
Fitted 6.6447E5 1.5092E6 6.4953E5 1.0063E6 unitless  
4 
B
d
N Gk   
Pathogen influenced 
neutrophil growth 
(denominator) 
Fitted 8.8322E4 1.7149E5 5.5590E4 9.0741E4 unitless 
5 8KN IL
k   
IL-8 induced 
neutrophil basal to 
killer phenotype 
transition 
Fitted 8.9617E3 4.9596E3 4.5302E4 2.6386E4 Hour-1 
6 8MN IL
k   
IL-8 induced 
neutrophil basal to 
migratory phenotype 
transition 
Fitted 4.8740E3 6.5289E3 2.9804E3 6.6655E3 Hour-1 
7 8K MN N IL
k  
 
IL-8 induced killer 
neutrophil to 
neutrophil migratory-
killer transition 
Fitted 3.9436 12.6137 5.9631 16.7691 Hour-1 
8 
8
d
IL Pk   
Pathogen induced IL-8 
production 
Fitted 1.2814E4 1.2646E4 1.2841E4 1.4198E4 CFU 
9 _filter offk  Filter decay rate Fitted 0.0813 0.0145 0.1407 0.0328 Hour
-1 
 
Once these differentiating parameters were identified, we put the model through a second 
round of estimation. In the second round, the model was fit to both data sets simultaneously; 
allowing only the seven previously identified key parameters to vary between the survivor and 
non-survivor subpopulations (see Table 4). Additionally, two fixed parameters were allowed to 
take different values across the two populations to maintain the appropriate initial conditions in 
creatinine and white blood cell count. This step resulted in two new parameter ensembles that 
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were identical in 28 parameters but varied in nine parameters. This second step enabled us to 
better crystallize the differences between animals that survived and those that died. These 
ensembles are biologically more relevant as we expect the animals’ immune responses to be 
highly similar, with small but important differences indicating susceptibility to a septic insult. 
Resulting full marginal distributions for each of the 7 parameters were statistically different 
across survivor and non-survivor populations (Figure 6– Box Plot). The final mean values and 
the standard deviation of all the estimated parameters are summarized in Table 3 and Table 4. 
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Figure 6. Posterior distributions of parameters allowed to vary across ensembles. 
3.3.2 Features of survivor and non-survivor dynamics 
3.3.2.1 Trained model outcomes 
The two ensembles resulted in model fits that faithfully recreate the key features of the surviving 
and non-surviving data sets (Figure 7– experimental fits).  Pathogen dynamics showed a transient 
behavior, with the model predicting a slightly higher peak for non-survivors. The ensembles 
captured the transient peak in IL-8 that occurs early after infection, with the non-surviving 
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population exhibiting a higher maximum peak. The predicted neutrophil populations also tracked 
well with the experimental results, with circulating basal neutrophils exhibiting a strong initial 
decline in abundance as the cells are activated and migrate to the site of infection, followed by a 
growth phase as the body compensates for the infection, and finally a return to baseline levels. 
While both surviving and non-surviving populations exhibited this trend, the surviving 
populations had a noticeably higher peak in basal neutrophils during the growth phase. Levels of 
neutrophil elastase / α1-PI complex in the blood, indicative of the killing and damage causing 
function of activated neutrophils, peaks around 15 hours post-infection. The non-surviving 
population showed a stronger and longer lasting peak, which is captured by the model. 
Creatinine, a measure of kidney health, increased to higher and more sustained levels in non-
surviving animals, as kidney health decreases and creatinine was not as efficiently cleared. 
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Figure 7. Simulated model fits with their experimental training data Mean (red), 25th-75th percentile (dark 
blue), and 5th-95th percentile trajectories of the simulated ensemble are shown. 
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3.3.2.2 Model Predictions 
The model also made predictions in the absence of observable data on the dynamics of 
neutrophil phenotypes (Figure 8–Neutrophil dynamics, Figure 9- Neutrophil phenotype box 
plot). Although both populations had similar peaks in fully activated neutrophils, allowing them 
both to fight off the infection on similar time scales as predicted experimentally, they showed 
strong differences in other populations. Non-survivors showed a significantly stronger spike in 
damage-causing killer neutrophils, while survivors showed a stronger spike in migratory 
neutrophils.  
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Figure 8. Model predictions for neutrophil phenotype dynamics following infection. 
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This can also be seen in the parameter ensembles, as neutrophils in non-survivors had an 
increased proclivity to activate their killing function in response to IL-8, while neutrophils in 
survivors were faster to activate their migratory functions (Figure 6– Box plot). Generating 
similar numbers of fully activated neutrophils, but through differing intermediate activation 
populations, could be an explanation for how these two animal populations controlled infection 
with similar dynamics, while still experiencing differing fates. 
 
 
Figure 9. Model predictions for maximal levels of each neutrophil phenotype compared across ensembles 
Maximal values for each neutrophil phenotype from each trajectory in both ensembles were recorded. 
 
 
  
 50 
At the receptor level, underlying activation of CXCR-1/2 was transient in both the 
survivors and non-survivors (Figure 10). Compared to the neutrophil dynamics which was slow 
and spread across few hours, receptor dynamics was very fast. Most of the receptors were in the 
free state, and internalized CXCR-1 is recycled faster than CXCR-2. Among the active receptors, 
there was one order of magnitude higher level of internalized CXCR-1 receptors than the surface 
bound CXCR-1 receptors, while this difference is two orders of magnitude for CXCR-2. Non-
survivors had higher levels of the surface and internalized active receptors. This can be explained 
by the higher peak in IL-8 levels for the non-survivors than the survivors (Figure 3 – 
Experimental fits). But, survivors had very close levels of CXCR-1 and -2 bound receptors and 
non-survivors had slightly higher levels of bound CXCR-1 than bound CXCR-2. These small 
differences in the peak levels of the receptors coupled with differences in the transition rates 
were sufficient to result in different neutrophil phenotype levels in the two populations, a key 
prediction from the ensemble modeling process.  
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Figure 10. Model predictions of receptor dynamics following infection. 
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3.3.3 Factors modulating cumulative damage in the two populations 
Until now, the focus was on deriving parametric ensembles explaining the mechanism of sepsis 
progression in each population. In this section, the sensitivity of sepsis-mediated damage to 
different model parameters (and hence different processes in the network) was evaluated for each 
population. Area under the damage curve (AUCD) was used as an output metric of cumulative 
damage from sepsis. The analysis was done in two steps. First the sensitive parameters affecting 
damage in each population was identified to check if similar parameters were responsible for 
modulating damage within each population. Next, the two populations were combined to identify 
the parameters primarily responsible a switch from a low to a high damage region. Since the 
model is highly nonlinear, a global sensitivity analysis (GSA) based on variance decomposition 
was chosen. This method decomposes the total variance in the output into variance and co-
variance contributions from each rate parameter and its higher order combinations. To reduce 
computational cost, a meta-model based approximation was done (See Materials and Methods). 
The meta-model method called Random Sampling High Dimensional Model Representation (or 
RS-HDMR), decomposes the output function (AUCD) into a set of component functions that 
includes the mean followed by first order effects of each parameter and other higher order effects 
resulting from parameter combinations. The degree of sensitivity of a parameter or its 
combination with other parameters (as a set) is captured by Sobol’ index which by definition is 
the fraction of the total output variance attributed to the selected parameter set. To perform GSA, 
4000 samples were generated from the parameter distributions of the two ensembles and the 
dynamics of the damage term was simulated for the survivors and the non-survivors. Figure 11A 
shows the AUCD distributions for each ensemble. As expected, the survivors show lower levels 
of cumulative damage than the non-survivors. The coefficient of variation was higher for the 
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non-survivors (CV = 1.98) as compared to the survivors (CV = 0.32). When GSA was performed 
on the survivor and non-survivor samples separately and in combination, it was found that a third 
order RS-HDMR contributed close to 95% of the variance for both the populations. However, 
most of the important contributions were from the parameters constituting highly ranked first 
order indices. Figure 11B-C shows the first order and total Sobol’ indices for the first five most 
sensitive parameters of each population and Figure 11E shows the results when both populations 
are combined. Note that the total Sobol’ index for each parameter, is the sum of first order index 
and all higher order indices involving that parameter. 
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Figure 11. Factors affecting cumulative systemic damage. 
 
  
 55 
For GSA conducted separately on the survivor and non-survivor ensembles, it is found 
that damage is mainly determined by the decay rate of the killer neutrophils, kNK  
(direction of 
influence shown in Figure 11D). The decay rate of the killer neutrophil controls the rate at which 
killer neutrophils are removed from the system, and the faster these neutrophils are removed, the 
lesser the damage. The next important term is the direct damaging effect of the killer neutrophils 
and this parameter has significant second order interactions with other parameters of the model 
as seen from the total sensitivity index. The next set of parameters has secondary importance and 
these parameters are different for the two populations (variance contributions of each parameter 
in this set is in the range, 1-10%). In survivors, damage is more influenced by the production rate 
of basal neutrophils and IL-8 in presence of the pathogen. In non-survivors, the effect is more 
pronounced for damage mediated IL-8 production (a positive feedback component), damage 
recovery term and killer neutrophil production rate. This indicates that overall damage in non-
survivors is more sensitive to the parameters associated with killer cells, IL-8 and damage. 
For GSA conducted on the combined population, the decay rate of killer neutrophils 
remains the most important parameter. Interestingly, the sensitivity value and ranking of three 
parameters increase relative to the case where the populations are analyzed separately. Among 
these, the transition rate of naïve neutrophils to the killer phenotype via CXCR1 ( ) is the 
most important parameter. The next two parameters include the decay rate in filter equation (7) 
(which determines the delay between pathogen generation and resulting neutrophil entry into 
circulation during sepsis) followed by the parameter controlling transition rate of killer 
neutrophil to the dual phenotype by CXCR2. Functional dependence of damage on these three 
parameters shows that they could be responsible for shift in the population from a low to a high 
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damage region. For example, Figure 11F shows the dependence of AUCD on parameter . 
Within each population, no particular trend is visible, but relative increase in the transition rate in 
the non-survivors correlates well with increased damage. Results in Figure 6 showed that the 
ranges of two of the parameters,  and k filter _off  were significantly different for the survivors 
and non-survivors. Results from sensitivity analysis support this prediction and further show that 
the parameter values correlate well with the transition in observed damage. 
3.3.4 Treatment Implementation 
Extracorporeal devices are emerging as promising therapies for treatment of sepsis 
[50,66,75,76]. In this instance we propose extracorporeal treatment which directly modulates 
CXCR-1/2 levels using a bioactive surface which interacts with unbound neutrophil surface 
receptors upon contact. Such a device, which is currently under development at the University of 
Pittsburgh, generates targeted and controlled downregulation of neutrophil surface receptors. The 
dynamics of this device can be analyzed within the framework of the generated computational 
model to determine its proof of principle in silico and help optimize treatment parameters. The 
proposed treatment implementation is shown in Figure 5. Specifically, the receptors are allowed 
to go to a trapped state and become unavailable for activation by IL-8 for the indicated time of 
treatment. To evaluate the potential of such an immunomodulatory treatment, we next performed 
an in silico trial by varying (1) the time when the treatment is introduced and removed and (2) the 
strength of interaction between the trapping device and the unbound neutrophil surface receptors. 
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For the analysis, the treatment initiation time was varied between 0 and 12 hours after the 
initial infection and the treatment discontinuation time was varied between 0 and 100 hours after 
infection. To modulate the treatment intensity, the device-receptor Kd was varied between the 
1x10-2 M and 1x10-5 M, with 2.5e-3 M representing the Kd of IL-8 and the receptors. The 
treatment was tested on a simulated population constructed by randomly selecting 69% of 
parameter sets from the non-survivor ensemble and 31% of parameter sets from the survivor 
ensemble, as observed in the experimental population. Survivor rate was measured for each set 
of proposed treatment parameters, as determined by the logistic regression classifier trained on 
the parameter ensembles with no treatment. A survivor rate above 31% was considered an 
improvement over baseline, and below 31% indicated the treatment causing overall harm. 
Figure 12 shows the survival rate following different treatment strengths and start-end 
times. In general, the optimal time for beginning treatment was between 3 and 6 hours after the 
original infection, resulting 40-80% survival rates depending on treatment strength. Starting the 
treatment after six hours was typically too late to have a strong effect on survival. Starting 
treatment within 3 hours of infection would often have neutral or deleterious effects, as it would 
dampen the initial inflammatory response that is critical to fighting off the infection. This led to 
an increase in pathogen growth and an increased late inflammatory response once treatment was 
removed. In the worst case scenarios following early treatment of a short duration, survival rates 
dipped as low as 13.2%, and this trend could be seen across all treatment strengths.  
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Figure 12. Effects of simulated treatment on animal survival rates Survival rates of a simulated population of 
animals following treatment with the proposed extracorporeal device considering a device-receptor affinity of 
(A) 1x10-2 M, (B) 1x10-3 M, (C) 1x10-4 M, (D) 1x10-5 M. In all cases the time of treatment was varied between 0 
and 12 hours post infection and ended between 0 and 100 hours post infection. 
 59 
When treated at the optimal time, survival rates increased from the 31% baseline to 
greater than 80% with sufficient device-receptor affinity. Using a Kd of 1e-2 M results in a 
maximum survival rate of 47%, and decreasing the Kd to 1e-3 M further increases this rate to 
80.3%. Further decreases in the Kd to 1e-4 M and 1e-5 M results in increases in survival rate to 
83.1% and 84.4%, showing there is a diminishing return to continuously increasing the device 
affinity. As the affinity increases, we see a new trend emerge in the simulation results, where 
treatment that begins as early as the onset of infection and  is significantly long lasting leads to 
increased survival rates, and a less strictly defined optimal treatment time (Figure 12D). In this 
case, the treatment is so strong and long-lasting that the inflammatory response is very strongly 
suppressed, implying that overwhelming pathogen growth leading to death cannot be reached 
within the bounds of this. However, this suppression of the immune system allows for significant 
pathogen growth and could leave the subject vulnerable to secondary infections which are not 
considered in this model. 
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Trends in response to treatment also appear to be robust to individual parameter values. 
The two most sensitive parameters kNK  and  were varied, increasing and decreasing each 
by 10% and 50% and recalculated the simulated population response to treatment (Figure 13 and 
Figure 14). In general response trends remained the same, with a defined peak in survivorship 
when treatment is administered 2-4 hours after infection. The magnitude of responses varied 
predictably, as strongly increasing kNK , the death rate of damage-causing neutrophils, resulted in 
a higher peak of survival. Conversely, increasing , which corresponds to a faster induction 
of damaging-causing cells, leads to a slight decrease in survivorship. Varying kNK  had a larger 
effect on these results, as expected following its identification as the model’s most sensitive 
parameter affecting damage (Figure 11).  
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Figure 13. Effects of varying Nk decay rates on simulated treatment. Survival rates of a simulated population 
of animals following treatment with the proposed extracorporeal device considering a device-receptor affinity 
of 1x10-3 M for k_Nk values of (A) 50% above, (B) 10% above, (D) 10% below, and (E) 50% below the 
baseline vale (C). In all cases the time of treatment was varied between 0 and 10 hours post infection and 
ended between 0 and 100 hours post infection. 
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Figure 14. Effects of varying Nk induction rates on simulated treatment. Survival rates of a simulated 
population of animals following treatment with the proposed extracorporeal device considering a device-
receptor affinity of 1x10-3 M for k_Nk_IL8 values of (A) 50% above, (B) 10% above, (D) 10% below, and (E) 
50% below the baseline estimated value (C). In all cases the time of treatment was varied between 0 and 10 
hours post infection and ended between 0 and 100 hours post infection. 
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3.4 DISCUSSION 
This manuscript discusses the development of a mechanistic computational model of IL-8 
mediated activation of CXCR-1/2 receptors in baboons which were administered intravenous E. 
coli. Neutrophil phenotypes, which dictate neutrophil functional response, were generated in silico 
based on CXCR-1/2 surface receptor levels, linking receptor level dynamics with neutrophil 
functional response. Parameter ensembles were generated for survivor and non-survivor 
populations, allowing for in silico observation of sepsis progression. Additionally, an 
extracorporeal treatment which modulates CXCR-1/2 levels on neutrophils was introduced in 
silico. This proof of concept evaluation allowed for preliminary device evaluation and optimization 
of treatment parameters. 
To our knowledge, this is the first model describing dynamic interactions of neutrophils 
which specifically takes into account information sharing between the systemic variables and the 
receptor levels. The receptor level dynamics of the model function on a rapid time scale, adjusting 
to systemic IL-8 levels in a matter of minutes. These changes in receptor signaling dictate changes 
in neutrophil phenotype, which dictates neutrophil function and hence mortality. This link thus 
provides a valuable mechanistic framework that can be subjected to clinically relevant treatment 
scenarios. For example, the experimental treatment could be implemented purely on the receptor 
level. Alternatively, systemic variables such as IL-8 levels or neutrophil phenotype could be 
modulated to evaluate performance of hemoadsorption or neutrophil sequestration extracorporeal 
devices.  
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Application of parallel tempering approach for parameter estimation allowed for the 
efficient generation of ensembles of parameters and resulted in a model that could fit experimental 
data well [115], allowing reasonably accurate simulations of the system without making strong 
claims about the values of single parameters which are notoriously difficult to measure and are 
likely to vary between individuals. This allows for robust, population-level predictions rather than 
point predictions of model parameters and model behavior. However, the computed multi-
dimensional posterior distribution in parameter space reflects constraints imposed by empirical 
data, as well as data sparsity and uncertainty. These constraints impose a covariance structure in 
the posterior distribution such that there is robustness in model behavior, despite large 
uncertainties in individual parameter values. Learning this structure is likely crucial in building 
predictive model [113,126]. Yet, the method is making no claim that individual parameter sets in 
the ensemble represent individuals in a population. At best, an individual could be represented by 
a smaller ensemble, reflecting uncertainty relating to this particular individual. Yet, it is fair to say 
that the ensemble is meant to represent uncertainly about a population of individuals, so that 
simulating the ensemble will provide expected behaviors across a population of individuals, as 
long as such behaviors are compatible with the empirical data used to generate the ensemble.  
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One trend that arose in the estimated parameter ensembles was a large difference in the 
magnitudes of different rate constants, sometimes spanning many orders of magnitude. This is not 
surprising, due to the inclusion of biological events spanning many time scales, ranging from fast 
molecular events to cell phenotype transitions and finally to the full duration of infections lasting 
for days. This suggests that future iterations of the model would benefit from a multiscale approach 
optimized towards handling these different time scales. Previous efforts [127–129] have worked 
out approaches that allow for efficient deterministic simulation of fast-scale molecular events, 
combined with more accurate stochastic simulation of slow-scale or rare events, and such 
techniques have resulted in impressive results [130,131].  
Sensitivity analysis on the parametric ensembles enabled identification of the relative 
importance of the model parameters to state variables of the model. In general, sensitivity analysis 
is an important step in systems biology workflows and provides valuable information on model 
characteristics [132,133]. Most models in the literature resort to a local analysis which is sufficient 
if the parameters are well defined. For nonlinear dynamic models based on sparse experimental 
data and for systems which have inherently high parametric uncertainty, a global analysis needs to 
be done. Global techniques perform combinatorial perturbations of the parameters utilizing 
samples from the high-dimensional space. Application of meta-modeling approximations via RS-
HDMR as was done in this work can significantly reduce the computational cost of sampling 
requirements for global methods. Additionally, if the sampling process takes into account 
parameter covariance computed from an ensemble model, biologically relevant sensitivity indices 
can be obtained. The systematic integration of ensemble modeling and global sensitivity analysis 
in this work allowed for identification of the parameters that control biological outcomes like 
sepsis induced tissue damage. 
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In addition to parameter fits, the behavior of the non-fitted state variables were inspected 
to check for features relevant to a clinical prognosis. Sepsis progression was analyzed by 
comparing differences between survivor and non-survivor populations. Neutrophil phenotypes in 
particular give insight into the differences between survivors and non-survivors. Of importance is 
the killer neutrophil population, which is highly elevated in the non-survivor population (see 
Figure 8 and Figure 9). This neutrophil phenotype is associated with neutrophil induced tissue 
damage in the model. With support from sensitivity analysis, killer neutrophil decay rate, which 
sets the levels and dynamics of NK, was found to be the most important contributor to total damage 
in both the populations. Multiple studies support this finding, indicating that non-survivors or those 
with more severe sepsis experience increased levels of neutrophil induced tissue damage and MPO 
generation [20,134–137] . Furthermore, the importance of this term is supported by studies on 
neutrophil apoptosis and lifespan. Research by Taneja [138] and Fialkow [139] determined that 
neutrophil apoptosis was reduced in cases of severe sepsis, leading to increased lifespan of primed 
and activated neutrophils. Damage caused by these neutrophils was partially responsible for the 
progression of sepsis in these severe cases. Upon completion of the combined GSA, was also 
found to be a significant contributor to total damage. Increase of this term leads to preferential 
generation of the NK neutrophil phenotype, which directly contributes to tissue damage. 
On the other hand neutrophils in the migratory phenotype were similar in survivor and non-
survivor populations. These findings agree with the data from Cummings et al [136] which found 
neutrophil’s harvested from septic and non-septic patients migrated to IL-8 at similar levels. 
Interestingly, survivors and non-survivors had similar levels of neutrophil kill/migrate phenotype, 
indicating that both ensembles had adequate neutrophil populations to eliminate the source 
pathogen. Therefore, the additional damage in non-survivors was neutrophil induced resulting 
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from elevated neutrophil killer phenotype levels. The IL-8 mediated killing functions of 
neutrophils are primarily triggered through CXCR-1 rather than CXCR-2. Modulation of CXCR-
1 levels in particular may reduce the killing neutrophil phenotype and reduce neutrophil induced 
organ damage. 
A number of experimental treatments for sepsis and other acute inflammatory diseases 
have targeted the CXCR-1 receptor with success in animal models [140–142]. However, 
translation to humans has been difficult for two main reasons [89]. First are inherent species 
dependent differences between human and animal immune systems that must be recognized and 
accounted for in pre-clinical studies. Second is the misuse of animal models and misinterpretation 
of pre-clinical data [143]. The recent debate on the translational fidelity of critical disease mouse 
models is a prime example where two separate comparisons of the human versus mouse genomic 
leukocyte responses using the same database resulted in two contradictory conclusions [144,145]. 
In the case of IL-8 signaling, which is not present in murine models, homologous cytokines and 
their associated surface receptors must be examined in IL-8’s place [146]. In this context, in silico 
modeling is an attractive alternative given that it allows preliminary evaluation of experimental 
human treatments at minimal costs.  
Multiple extracorporeal sepsis treatments are currently under investigation with promising 
results. Blood purification techniques such as hemoadsorption [50,66,147–149]  allow for 
cytokines and other detrimental proteins to be removed directly from the blood during the cytokine 
storm, curbing the patient’s immune response. Another approach called activated neutrophil 
sequestration [75,150], selectively removes harmful neutrophil phenotypes from circulation. In 
this instance we propose extracorporeal treatment which directly modulates CXCR-1/2 levels 
using a bioactive surface which interacts with unbound neutrophil surface receptors upon contact, 
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resulting in CXCR-1/2 downregulation. This approach is advantageous because no components of 
blood are removed from circulation, allowing for a healthy immune response after appropriate 
modulation of neutrophil surface receptors. In addition, all necessary cell-cell interactions are 
allowed to occur within well-controlled microcirculation of the device. Such a setup also allows 
treatment to be easily titrated or halted by adjusting blood flow through the device. The dynamics 
of such a device were analyzed within the framework of the generated ensemble model to 
determine its proof of principle in silico and to evaluate its benefits in rescuing individuals marked 
as non-survivors by the parameter ensembles. 
When evaluated in silico the proposed extracorporeal CXCR-1/2 modulation device 
improved mortality from 31% to above 80% when deployed under certain ranges of conditions. 
This substantial improvement in survival supports the hypothesis that a CXCR-1/2 modulatory 
device may improve patient outcomes. However, time and length of treatment implementation are 
critical parameters tied to this success. The importance of quickly beginning sepsis treatment has 
been well established [151], particularly for antibiotic administration. Our simulations showed a 
well-defined optimal time for the initiation of treatment, between 3 and 6 hours after the onset of 
severe infection. Treatment, if started within this time frame, had a high degree of success over a 
large range of treatment durations and strengths. This window is specific to the animal model under 
study and will not directly translate to a clinical setting for two main reasons. First, the model was 
calibrated with experimental data obtained from baboons, and differences between the baboon and 
human immune systems must be considered.  Second, the baboons were exposed to a well-
controlled bacterial infusion at a known time point, followed by a predictably quick and strong 
immune response. In this instance the pathogen load is well controlled and a large portion of the 
ensemble can therefore be addressed by a single treatment setting. In clinical practice, patients 
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present with varied pathogen loads and they may be in different stages of infection and immune 
response. So, future experiments will need to combine clinical knowledge with additional data 
gathering and simulation to obtain treatment timing relevant for human patients.  
Clinicians are actively searching for biomarkers to track sepsis disease progression and 
prescribe treatment [152–154]. Neutrophil phenotype may be a valuable indicator of disease state 
and individual patient response, but this information is difficult to collect in the clinic. Currently 
neutrophil phenotype can be evaluated either through functional testing or flow cytometry analysis 
of critical neutrophil surface receptors. In addition to CXCR-1/2 which are the focus of this model, 
CD11b, CD88, and CD62L all have roles in dictating neutrophil phenotype [155] and surface 
receptor expressions vary depending on severity of the inflammatory response. To more readily 
exploit phenotype data it may be possible to map neutrophil function to easily measurable 
biomarkers. Using these indirect measures of neutrophil phenotype can guide clinicians to ideal 
treatment regimens.   
In conclusion, the ensemble model presented in this report provided key insights into the 
progression and mechanisms involved in progression of sepsis. We underline the role of relative 
abundance of killer, migratory and dual neutrophil phenotypes in deciding survivorship in an 
animal model. In addition, an in silico extracorporeal treatment which modulates CXCR-1/2 
neutrophil surface receptors showed promising results. Further study and collection of 
experimental data will help further refine both the model and experimental device. Incorporation 
of data from a diverse patient population and expansion of current ensembles would increase the 
model’s generalizability, improving the potential for translation. Additional model parameters 
related to the device such as flow rate, surface area, and form factor could be included, allowing 
the model to streamline device development. 
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4.0  CONSTRUCTION AND EVALUATION OF AN EXTRACORPOREAL DEVICE 
TO MODULATE CXCR-1 AND CXCR-2 NEUTROPHIL SURFACE RECEPTOR 
EXPRESSION            
This chapter discusses the development of an extracorporeal device that can “reprogram” 
neutrophils to attenuate their chemotactic response to IL-8 as a potential treatment for sepsis. The 
Neutrophil Reprogramming Device (NeRD) is essentially a hemodialyzer cartridge in which IL-8 
is covalently bound to the inner lumens of the dialyzer fibers. Similar to hemodialysis, blood is 
perfused through the NeRD and neutrophils, which naturally marginate toward the fiber inner 
lumens, interact with the immobilized IL-8 through CXCR-1 and CXCR-2 surface receptors, the 
same interaction that causes chemotaxis. As a result of the interaction, the CXCR-1/2 receptors 
internalize and CXCR-1/2 surface expression on neutrophils is down-regulated, thus reducing the 
neutrophils chemotactic response to IL-8 as blood is perfused back into the patient. The neutrophils 
maintain the ability to target and eliminate bacteria in infected tissue through secondary CXCR-
1/2 independent cell signaling pathways involving N-formyl-metyl-leucyl-phenyl (fMLP), a 
byproduct of bacterial destruction. We hypothesize that the reduced chemotactic response to IL-8 
will reduce the redirection of neutrophils into healthy tissue and reduce sepsis induced organ 
failure. Multiple device configurations are presented in this chapter, presenting the progression of 
results and testing. Each subsequent configuration built of the past, eventually leading to some of 
the concepts presented in the next chapter. 
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4.1 INTRODUCTION 
Sepsis is a severe systemic inflammatory response due to an infection and affects 900,000 
Americans per year. The incidence of sepsis is expected to increase over the next 10-20 years as 
the population ages [1]. Despite improvements in care, the hospital mortality rate associated with 
sepsis has remained persistently high and is nearly 20% [1,5,6]. We’ve recently shown that at one 
year survival is less than 60% for patients with septic shock [156]. Sepsis is now the leading cause 
of in-hospital death in the United States [1,8], yet there are currently no FDA approved specific 
treatments for sepsis. Intensivists essentially can only manage the symptoms of sepsis until the 
patient’s immune system naturally recovers, if it does so. The current standard of care for sepsis 
is treatment of the causal infection with source control and antibiotics, while providing necessary 
organ support using drugs (e.g. vasoactive medication) or devices (e.g. hemodialysis, mechanical 
ventilation, etc.) [9]. Drug therapies to suppress the immune response such a corticosteroids [3] 
are occasionally used but run the risk of immune suppression and an inability to eliminate the 
causal infection. Experimental drug therapies to attenuate pro-inflammatory cytokines such as 
tumor necrosis factor (TNF) and interleukin-1 (IL-1) have had little success [4]. Device therapies 
including hemofiltration and hemoadsorption broadly modulate cytokine levels [48,49], but 
neutrophils do not deactivate once systemic cytokine concentrations fall. Instead, cytokines such 
as IL-8 that spilled into the bloodstream from inflammation at the site of infection diffuse into 
healthy tissues and organs [157,158]. Activated neutrophils sense these elevated cytokine levels 
and infiltrate into healthy tissues and organs, where they can cause severe organ damage and 
eventually sepsis induced organ failure [159]. 
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Neutrophils are the first responders to sites of inflammation and play critical roles in the 
innate immune response. Normally, neutrophils migrate from the bloodstream into the infected 
tissues due to inflammation there by sensing chemical gradients of the chemokine IL-8, which is 
released by macrophages in response to foreign invaders like bacteria. The IL-8 chemokine binds 
to the expressed neutrophil cell surface receptors CXCR-1 and CXCR-2 and induces chemotaxis 
to the site of infection [2]. The increased neutrophil activity in sepsis, however, results in 
undesirable systemic-level inflammation and elevated IL-8 levels in healthy tissues and organs 
[26,27]. Activated neutrophils then infiltrate these tissues/organs where they can damage cells and 
lead to multiple organ dysfunction [2,28]. The lung is especially susceptible to sepsis induced 
organ failure. Again, potential treatments that indiscriminately suppress the activity of neutrophils 
can cause immune suppression and the inability to clear the causal infection [15,29,30].  
4.2 MATERIALS AND METHODS 
4.2.1 Module construction 
Scaled down prototype modules were constructed from loose dialyzer fibers and in a polycarbonate 
housing. Housing bodies were constructed from 0.250” outer diameter, 0.125” inner diameter 
polycarbonate tubing (see Error! Reference source not found.). The ends of each housing were 
odified to accept standard luer connecters for tubing connections and blood flow. Luer tubing 
connectors were also placed in the outer dialysate compartment to facilitate shell side washing. 
Twenty-five loose dialyzer fibers were loaded into housings and potted in place using UV cure 
adhesive (Dymax). Aminated dialyzer fibers were provided by Fresenius or Gambro for 
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evaluation. The fibers provided by both companies were modified versions of off the shelf 
commercial devices. Fresenius fibers were PS base material, while Gambro fibers were AN-69 
acrylonitrile and sodium methallylsulfonate copolymer based. 
 
 
Figure 15. Scaled down leukocyte reprogramming test module. 
4.2.2 Cytokine immobilization 
Alternately, polymethylpentene (PMP) oxygenator fibers (Oxyplus™; OD: 380 µm, ID: 200 µm) 
were obtained from Membrana GmbH (Wuppertal, Germany) were evaluated in the same module 
housing. The shell side luer attachments were utilized for blood flow in this configuration. All 
module construction methods are variations of previous mini-modules constructed in the Medical 
Devices Laboratory for gas exchange [160–162]. 
4.2.3 Recirculation loop setup 
Setup and evaluation of modified modules requires recirculation of buffer or blood through the 
module. The setup includes a buffer/blood reservoir. A 10ml beaker is typically used for this 
purpose. This reservoir is typically placed in a larger beaker to for stability. This reservoir is placed 
on a shaker plate (Hedolph Titramax 101) at 300 rpm to agitate the reservoir contents. 32” 
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Masterflex L/S 13 tubing leads from the reservoir through a pre-calibrated Masterflex L/S 
peristaltic with easy-load pump head. The tubing connects to the scaled-module then returns to the 
reservoir by a 16” length of tubing. An example flow loop is shown in Error! Reference source 
ot found.. Unless otherwise noted a flow rate of 1 ml/min is utilized for buffer or blood 
recirculation.  
 
 
Figure 16. Standard blood recirculation loop. 
 
A stop-flow configuration was tested with different module and immobilization setups. In 
this configuration, the pump was programmed to flow at 1ml/min for 45 seconds, followed by a 
45 second incubation period. This flow configuration allows for neutrophil margination during 
flow, and complete clearance of the module, followed by a period of no flow to allow neutrophil 
interaction with the modified surface. 
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4.2.4 IL-8 immobilization 
Protein immobilization procedures were completed using buffers circulated in the configuration 
explained above and shown in Error! Reference source not found.. Each procedure is described 
n detail below. 
4.2.4.1 Chitosan spacer immobilization 
A chitosan spacer approach has previously been utilized for enzyme immobilization in the Medical 
Devices Laboratory [160,161]. The entire method is represented schematically in Figure 16. This 
process requires an aminated surface to facilitate further conjugation steps. Chitosan (MW 50-
190kD), glutaraldehyde, acetic acid, and other reagents were obtained from Sigma-Aldrich. 
Commercially available polymethylpentene hollow fibers (Oxyplus™; OD: 380 µm, ID: 200 µm) 
were obtained from Membrana GmbH (Wuppertal, Germany). These fibers were cut into 27 fiber 
wide fiber mats and washed three times in 0.5% Tween-20 in 100mM Sodium Phosphate buffer 
pH 8.5 then rinsed thoroughly with distilled deionized water. After washing, PMP fibers were 
amine functionalized using plasma enhanced chemical vapor deposition (PECVD) with a PVA 
TePla Ion 40 system according to a technique established by Arazawa et al [163]. Briefly, the pre-
cut hollow fiber membrane samples were added to the vacuum chamber in a single layer. Upon 
adding samples, the chamber was evacuated to 50 mTorr. Allylamine was introduced to the 
chamber at a rate of 180 mL/min and 300 W of power at 150 Hz and a 20% duty cycle was 
introduced for 5 min. Samples were removed and immediately rinsed three times with 0.5% 
Tween-20 in 100 mM phosphate buffer pH 8.5 then thoroughly rinsed with deionized water.  
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Figure 17. Chitosan immobilization process 
 
 
 Functionalized fiber mats were placed into 60ml glass culture tubes. 50ml 5% 
glutaraldehyde with 0.33 g sodium cyanoborohydride was added to the tube and placed on a rotary 
mixed for 15 minutes at 15rpm. The fibers were then rinsed two times with 100mM phosphate 
buffer pH 8.5 for 10 minutes, followed by a final rinse with 1% acetic acid to change fiber surface 
pH to reduce potential non-specific chitosan deposition. 1% low viscosity chitosan with sodium 
cyanoborohydride reducing agent was dissolved in 1% acetic acid and filtered with 60µm 
MILLIPORE filter and added to each fiber mat for 15 minutes on a rotary mixer. The fiber mat 
was then rinsed one time with distilled deionized water, then 3x with phosphate buffer. Addition 
of 5% glutaraldehyde solution and washing was repeated to facilitate conjugation of the chitosan 
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spacer. Finally, 50µg of IL-8 or the molar equivalent of BSA was added to the fibers in 10mL 
phosphate buffer and recirculated for 1 hour. 3x washing with phosphate buffer was completed to 
remove non-specifically bound protein. 
4.2.4.2 PMP Fiber Scanning Electron Microscopy 
Fibers were imaged using Scanning Electron Microscopy (SEM) to observe the presence and 
uniformity of the immobilized chitosan layer. A JSM 6335F SEM at the Center for Biological 
Imaging at University of Pittsburgh was utilized. PMP fiber samples were immobilized using the 
procedure described above. Samples were washed in distilled deionized water to remove residual 
salts. After drying under vacuum samples were cut into 1cm x 1cm fiber mat squares and attached 
to ferrules using double sided tape. Samples were sputter coated with gold/palladium then 
visualized under SEM at 300-10000x magnification. Three images of each magnification were 
randomly selected to be representative of the entire fiber surface. 
4.2.4.3 PEG Immobilization 
PEG immobilization was utilized with Fresenius aminated fibers, Membrana PMP fibers, and 
Gambro AN-69 aminated dialyzer fibers. This approach utilized a heterobifunctional PEG spacer 
to crosslink surface amines to a protein [164]. The flexibility of the PEG chain and increased 
distance from the fiber surface is hypothesized to decrease steric hindrance and increase protein 
activity [165,166]. This immobilization approach is detailed in Figure 18. 
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Figure 18. PEG spacer immobilization schematic. 
 
 
For Fresenius and Gambro dialyzer fibers the following procedure was used by 
recirculating reagents through prepared minimodules. First complete single pass wash of 100mM 
sodium phosphate buffer pH 7.5 through the inner lumen of fibers for 15 minutes at 1.0 mL/min 
and flush shell side with 50ml phosphate buffer to clean fibers. Prepare beaker with 15ml with 
100mM phosphate buffer pH 7.5. Working quickly under nitrogen flush add 40ul of 50mM NHS-
PEG-COOH in DMF and recirculate through module at 1mL/min for 60 minutes. Remove excess 
reagent then complete single pass was with sodium phosphate buffer pH7.5 for 20 minutes at 
1ml/min and flush shell side with 50ml of buffer. Switch wash buffer to 50mM MES pH 6.0 
solution with 0.5M NaCl. Run single pass wash for 10 minutes and rinse shell side with 50 mL 
MES buffer. To prepare EDC/NHS solution for 2 modules, add 9.2mg EDC and 26.1mg sulfo-
NHS to 24mL 50mM MES pH 6.0 + 0.5M NaCl immediately before use. Aliquot 12mL solution 
for each module and recirculate for 15 minutes at 1 mL/min. Discard solution and quickly rinse 
inner lumen with phosphate buffer pH 7.5 for 5 minutes and shell side with 50mL phosphate buffer. 
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Add 10mL phosphate buffer for each module. Add 50ul IL-8 or molar equivalent of control protein 
to solution. Recirculate protein solution for 1 hour at 1mL/min. After immobilization, complete 
planned was protocol as described below. 
For PMP oxygenator fibers a similar procedure was followed, but immobilization was 
completed in test tubes prior to potting of fibers inside minimodules. 
4.2.5 IL-8 ELISA and wash protocols 
IL-8 ELISAs (Invitrogen KHC0084 or KHC0081) were utilized to determine the effectiveness of 
multiple wash protocols. After completion of the wash protocol, 5% bovine serum albumin in 1x 
DPBS was recirculated through modules at 1mL/min for 60 minutes. Sample from this buffer 
recirculation was used in ELISA testing to determine IL-8 concentration in the effluent. In 
conjunction with neutrophil recirculation buffer (NERB) testing, which is described below, these 
results are used to determine what degree of washing is necessary to eliminate functional levels of 
soluble IL-8 leaching during device testing. Testing followed Invitrogen directions, described 
briefly below. Both ultrasensitive and standard ELISAs were used for testing. First, a standard 
curve was prepared using the provided IL-8 standard which was serially diluted to cover the entire 
test range. In addition to undiluted samples, effluent was diluted 10x or 100x to cover a larger 
range of IL-8 concentrations. Effluent was diluted in the standard effluent buffer. 100ul of each 
sample was loaded into the ELISA strips, leaving 2 blank for chromogen blank controls. The plate 
was covered and left at room temperature for 2 hours. Washing was completed using the provided 
wash buffer and a plate washer. Each wash step was comprised of 4x wash and aspiration of each 
well. Next a biotin conjugate was added and incubated for 1 hour at room temperature. After wash 
and aspiration, the streptavidin working solution was diluted and added to each well for 30 
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minutes. Washing and aspiration was completed again, followed by addition of stabilized 
chromogen. Samples were incubated in the dark for 20 minutes then stop solution was added to 
each well. A plate reader was used to read absorbance at 450nm and effluent samples were 
compared to the standard curve to calculate IL-8 concentration. Finally, high salt concentrations 
and increased pH were also evaluated. 
Standard wash protocols use the same recirculation setup as immobilization. Early wash 
protocols include only recirculation of 100mM phosphate buffer to remove unbound IL-8. 
Additional washing includes a 1-2 hour single pass wash of 100mM phosphate buffer pH7.5 + 
0.5% Tween-20 with and without 5% BSA. Other washes include use of 5% BSA in 1x PBS for 
1-16 hours. Other protein solutions including fetal calf serum of casein solutions were also tested. 
3M NaCl with 100mM sodium phosphate buffer pH 8.5 were tested to remove unbound IL-8. 
Shell side washing in a cross flow configuration to inner lumen flow was also utilized for 
some tests. A flow rate of 2mL/min with the same wash solutions as the inner lumen was completed 
to encourage transport across membranes and remove unbound protein and reagents from the shell 
side. 
4.2.6 Neutrophil buffer recirculation (NERB) assay 
A neutrophil buffer recirculation (NERB) assay is utilized to determine if the level of IL-8 leaching 
from modified fibers in high enough to cause a functional change in neutrophil receptor expression. 
Using the standard recirculation setup, 10mL of 5% BSA in DPBS is recirculated through both IL-
8 modified and BSA modified modules for 60 minutes.  Additionally unmodified 5% BSA is used 
a negative control and 5% BSA spiked with 1 ug/ml IL-8 is used as a positive control. 200ul 
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samples from the recirculation reservoirs or control beakers were taken at 60 minutes. An 
additional time point is potentially collected at 30 minutes if time course data is desired.  
After collection of all samples, 200ul of whole blood is added to each sample and vortexed 
briefly at low speed. The samples are placed on a shaker plate for 20 minutes. After the incubation, 
each sample is split into 2 200ul samples (isotype and non-isotype) for flow cytometry testing. All 
antibodies were purchased from BD. For isotype testing 20ul of APC isotype control, 20ul PE 
isotype control, and 20ul CD15 FitC stain are added to each sample. For non-isotype sample 20ul 
CD182 APC, 5ul CD181 PE, and 20ul CD15 FitC antibodies were added to each sample. These 
sample were mixed then incubated for 30 minutes in the dark. After incubation, 1.5mL FACS Lyse 
was added to each sample, then thoroughly mixed and incubated for 10 minutes on a mixer in the 
dark. Samples were centrifuged for 5minutes and 500g then the supernatants were aspirated. 1% 
BSA in DPBS washing was completed two times to remove lysed erythrocytes and stains. After 
washing 300ul 4% formaldehyde in PBS was added for storage until flow cytometry could be 
completed. 
Flow cytometry was completed using a MACSQuant Analyzer 10. Analysis was completed 
using Winlist software. Neutrophils gated using SSC vs FSC plots and verified for CD15+ staining. 
Mean fluorescent intensity (MFI) was calculated in non-isotype samples for both CD181 and 
CD182 after subtraction of isotype sample MFI. Compensations were applied using single stained 
cell samples. Analysis was completed by comparing test samples to baseline blood to generate 
relative receptor express of CXCR-1/2 (CD181/CD182). 
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4.2.7 Blood recirculation and receptor characterization  
After completion of the NERB assay, blood recirculation is completed to determine ex vivo device 
performance with freshly drawn human blood from healthy volunteers. The protocol was approved 
by the University of Pittsburgh Instructional Review Board to protect volunteers. A loop is 
established as in Error! Reference source not found. to facilitate blood recirculation. Before 
lood, DPBS heparin solution is perfused through the circuit for 10 minutes. For each module, 
10mL of freshly drawn whole blood is placed in a beaker. For controls 10mL whole blood is placed 
in a falcon tube. All containers are placed on a mixer plate to ensure blood is well mixed and does 
not settle. Pre-calibrated pumps are started with a flow rate of 1mL/min as the loop is de-primed 
of the DPBS heparin solution. Once blood enters the modules, the free IL-8 positive control is 
spiked with 1ug/ml IL-8 and 0 minute time point samples are taken from baseline blood (negative 
control). For each sample, two 100ul aliquots (isotype and non-isotype) are taken from the beaker 
or falcon tube. Samples are stained using the same protocol as the NERB assay.  
After addition of stains, samples are incubated for 30 minutes in the dark. FACS lyse is 
added to samples and incubated for 10 minutes prior to centrifugation at 5min 500g. Samples are 
then washed 2x times with 1% BSA. After the final wash 300ul of 4% formaldehyde solution in 
PBS. In addition to the baseline 0 time point, samples for all modules and controls was gathered 
at 60 minutes. Additional time points were occasionally added to collect additional time course 
data. Often a sample was taken of isolated neutrophils immediately before initiating the Boyden 
chamber chemotaxis assay. Staining of isolated neutrophils followed the same protocol as whole 
blood, except initial sample volume was only 50ul of final neutrophil solution. Analysis of CXCR-
1/2 receptor expression was completed using the same protocol as for the NERB assay, gating for 
neutrophils then comparing relative change in mean fluorescent intensity. 
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4.2.8 Boyden chamber chemotaxis assay 
A Boyden chamber based chemotaxis assay is used to determine if ex vivo recirculation tests 
have a functional impact on neutrophil migration [167,168]. The assay works by quantifying the 
number of neutrophils which migrate through a polycarbonate membrane towards a 
chemoattractant in the bottom chamber.  
 
 
Figure 19. Boyden chamber chemotaxis assay. 
 
Corning HTS Transwell 96 well plates are utilized for testing. Membranes and wells are 
incubated with a 2.5mg/mL fibrinogen solution then washed 3x times with DPBS. Plates are left 
to dry in a hood prior to loading with neutrophils. 
After recirculation, neutrophils must be isolated from whole blood to prevent clogging of 
the membrane filter. Magnetic separation was completed using MACSxpress neutrophil isolation 
kit (Miltenyi Biotec 130-104-434). Non-target white blood cells are removed using antibody 
tagged magnetic beads and red blood cells are separated by sedimentation and a secondary 
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magnetic bead isolation step. First magnetic particles are suspended according to manufacturer’s 
instructions. These beads are added to whole blood samples immediately after recirculation testing. 
After a 5 minute incubation, samples are placed in the magnetic separator for 15 minutes. The 
supernatant, which includes neutrophils and residual erythrocytes, is harvested and placed in a 
clean tube. Reconstituted beads with antibodies targeted erythrocytes are then added and allowed 
to incubate for 5 minutes. After 10 minutes of separation the supernatant, which contains isolated 
neutrophils, is collected. Samples are centrifuged for 5 minutes at 250g then suspended in 2.5ml 
DPBS. 50ul samples are collected for flow cytometry receptor analysis and cell counting to 
determine neutrophil concentration. 
To prepare the assay chemoattractants must be added to the bottom well. The 
chemoattractants are diluted to predetermined concentrations in DPBS. Typically, unmodified 
DPBS, 5nM IL-8, 100nM IL-8, 100nM fMLP, and 100nM GRO-α are tested in quadruplicate for 
each assay. Next, pre-isolated neutrophils are loaded into the top well of the plate. A typical plate 
configuration is shown in Figure 19. After the entire plate is loaded it is placed in a 37˚C incubator 
with 5% CO2 for 40 minutes. The plate is then removed from the incubator and 20ul of 0.5M 
EDTA is added to each well. The plate is placed in a 4˚C refrigerator for 10 minutes to facilitate 
neutrophil release from the membrane. 200ul samples from each well are then placed in labelled 
flow cytometry culture tubes. 300ul 4% formaldehyde is added to each sample in preparation for 
flow cytometry counting the following day. 
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Figure 20. Typical Boyden chamber 96-well plate layout. 
 
Flow cytometric counting of neutrophils was completed using a MACSQuant Analyzer 10. 
Analysis was completed using Winlist software. Neutrophils were gated using SSC vs FSC plots 
and counted to estimate total number of migrated cells. Mean number of neutrophils were 
calculated from the four duplicates. Occasionally samples were omitted if air bubbles were visible 
in the well after membrane removal. These were reloaded if possible. Percentage of migrated 
neutrophils was calculated by dividing the average number of migrated neutrophils by average 
number of loaded neutrophils for each test iteration. 
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4.3 RESULTS 
4.3.1 PMP oxygenator fibers with chitosan spacer 
Initial testing of PMP oxygenators utilized a branched chitosan spacer. The chitosan layer was 
covalently bound to aminated fibers using glutaraldehyde. A secondary glutaraldehyde step was 
used to immobilize the target protein. The high viscosity of chitosan prevented use of this 
technique with dialyzer fibers. Blood recirculation testing resulted in 34% and 29% 
downregulation of CXCR-1 and CXCR-2 respectively at 60 minutes relative to baseline blood. 
The BSA modified module showed similar levels of downregulation to the IL-8 module. The free 
IL-8 positive control exhibited 75% and 89% reduction in CXCR-1/2 expression. Results are 
shown in Figure 21 and Figure 22. 
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Figure 21. CXCR-1 expression after recirculation through PMP fiber modules with chitosan spacer. 
 
 
Figure 22. CXCR-2 expression after recirculation through PMP fiber modules with chitosan spacer. 
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 Boyden chamber chemotaxis testing results are shown in Figure 23. Low chemokenesis 
was observed in all samples, with less than 5% of cells migrating through the filter. Baseline blood 
exhibited a strong migratory response toward 100nM IL-8, with 87% of neutrophils migrating 
through the filter. Baseline migration towards 100nM fMLP was lower than IL-8 but still 
significantly higher than baseline. The free IL-8 positive control neutrophils exhibited reduced 
migration towards IL-8, with only 24% of cell migrating. Chemotaxis towards fMLP was 
equivalent to baseline blood samples. Both IL-8 and BSA modules experienced increased 
chemotaxis to IL-8 and fMLP relative to baseline. 
 
 
Figure 23. Neutrophil migration in Boyden chamber chemotaxis assay after recirculation through PMP fiber 
modules with chitosan spacer. 
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4.3.2 PEG spacer 
An updated immobilization approach utilized a heterobifunctional PEG spacer in place of chitosan. 
This eliminated the use of glutaraldehyde from the procedure. The testing results are shown in 
Figure 24 and Figure 25. Free IL-8 positive control induced substantial CXCR-1/2 
downregulation, particularly in CXCR-2 which was reduced 98% relative to baseline blood. After 
60 minutes of recirculation, CXCR-1 expression was reduced 28% in the IL-8 control module and 
23% in the BSA modified module. CXCR-2 downregulation was more substantial for the IL-8 
module, resulting in 59% downregulation. The BSA modified module induced 41% 
downregulation.  
 
 
Figure 24. CXCR-1 expression after recirculation through PMP fiber modules with PEG spacer. 
 90 
 
Figure 25. CXCR-2 expression after recirculation through PMP fiber modules with PEG spacer. 
 
 Chemotaxis testing results are shown in Figure 26. Low chemokenesis was observed in all 
samples. The free IL-8 (1 ug/mL) positive control showed migratory shutoff towards 100nM IL-
8, but maintained migratory activity towards fMLP. The BSA control module and IL-8 both 
experienced minimal change in migratory activity compared to the untreated baseline control. A 
small reduction in mean migration between untreated and IL-8 module neutrophils towards 100nM 
IL-8 is not statistically significant. 
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Figure 26. Neutrophil migration in Boyden chamber chemotaxis assay after recirculation through PMP fiber 
modules with PEG spacer. 
 
4.3.2.1 Fresenius fibers 
Aminated polysulfone dialyzer fibers, provided Fresenius, were conjugated using the PEG spacer 
protocol discussed above. The modules and flow loop were configured for flow and modification 
on the fiber inner lumen. A NERB buffer recirculation test was completed to determine if leaching 
was at a functionally relevant level. The free IL-8 positive control induced downregulation in both 
CXCR-1/2. Neither the hAlbumin nor IL-8 modules induced significant CXCR-1/2 
downregulation. Results are presented in Figure 27 and Figure 28. 
 
 92 
 
Figure 27. NERB buffer recirculation results showing neutrophil CXCR-1 expression after exposure to buffer 
circulated through modified aminated polysulfone fibers. 
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Figure 28. NERB buffer recirculation results showing neutrophil CXCR-2 expression after exposure to buffer 
circulated through modified aminated polysulfone fibers. 
 
Whole blood recirculation was completed to determine the test module’s impact on CXCR-
1/2 expression. These results are shown in Figure 29 and Figure 30. At 60 minutes the free IL-8 
positive control induced significant downregulation relative to baseline blood. Both the IL-8 and 
hAlbumin module induced downregulation in both CXCR-1 and CXCR-2. hAlbumin control 
downregulation was greater than the IL-8 module for CXCR-1, but less substantial in CXCR-2, 
where the IL-8 module induced greater levels of downregulation. The 150 minute time point 
measured CXCR-1/2 expression after the 90 minute neutrophil isolation procedure. Only minor 
changes in CXCR-1/2 expression relative to the 60 minute time point were observed. 
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Figure 29. Neutrophil CXCR-1 expression after recirculation through modified aminated polysulfone fibers. 
 
 
Figure 30. Neutrophil CXCR-2 expression after recirculation through modified aminated polysulfone fibers. 
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 Boyden chamber chemotaxis results are shown in Figure 31. Chemotaxis results show 
slightly elevated chemokenesis for all but baseline blood samples. Baseline blood, hAlbumin 
control module, and the IL-8 test module all exhibited strong migration towards all chemokines. 
The free IL-8 positive control showed migratory shutoff towards 5nM IL-8 and GRO-α, but 
maintained migratory response towards 100nM IL-8 and fMLP. 
 
 
Figure 31. Neutrophil migration in Boyden chamber chemotaxis assay after recirculation through modified 
aminated polysulfone fiber modules with PEG spacer. 
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4.3.2.2 Gambro fibers 
Aminated AN69 fibers were provided by Gambro for evaluation with the PEG 
immobilization. These fibers were modified using the same module, immobilization, and test 
procedure as the Fresenius-PEG fibers. Multiple donor tests were completed with the same 
immobilization procedures, with minor changes to the wash protocol, to better understand donor 
variability. Test 1 did not include a NERB assay, but additional tests included the buffer 
recirculation. 
After whole blood recirculation, CXCR-1 and CXCR-2 downregulation was significant for 
the free IL-8 positive control, registering 68% and 92% respectfully. These results are shown in 
Figure 32 and Figure 33. The hAlbumin test module closely tracked baseline blood samples. The 
IL-8 module induced significant downregulation of both CXCR-1 and CXCR-2. At 60 minutes the 
modules reached 52% CXCR-1 and 88% CXCR-2 downregulation. CXCR-2 downregulation after 
recirculation through the IL-8 module nearly reached the levels achieved in the free IL-8 control. 
All CXCR-1 and CXCR-2 expression levels were fairly consistent at both 60 and 150 minutes. 
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Figure 32. Neutrophil CXCR-1 expression after recirculation through modified aminated Gambro AN69 
fibers. 
 
 
Figure 33. Neutrophil CXCR-2 expression after recirculation through modified aminated Gambro AN69 
fibers. 
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Boyden chamber chemotaxis testing results are shown in Figure 34. Analysis of the results 
show high levels of migration towards all chemoattractants in the baseline neutrophil samples. 
Free IL-8 neutrophils exhibited slightly increased chemokenesis and migratory reduction relative 
to baseline in 5nM IL-8 and GRO-α chemoattractants. Migration remained consistent with 
baseline neutrophils towards 100nM IL-8 and fMLP. HAlbumin module treated neutrophil 
migration was equivalent to baseline blood migration. IL-8 module treated neutrophils experienced 
a similar reduction in migration as the free IL-8 control. With reduced migration towards 5nM IL-
8 and GRO-α chemoattractants. 
 
 
Figure 34. Neutrophil migration in Boyden chamber chemotaxis assay after recirculation through modified 
aminated Gambro AN69 fiber modules with PEG spacer. 
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NERB testing was completed in the second Gambro-PEG fiber recirculation test. The free 
IL-8 positive control induced downregulation in both CXCR-1/2, while hAlbumin control module 
closely tracked the baseline. The IL-8 module did not induce significant downregulation in CXCR-
1 (Figure 35). However, there was substantial downregulation compared to baseline in CXCR-2, 
which led to a 39% reduction in CXCR-2 expression at 60 minutes (Figure 36). 
 
 
Figure 35. NERB buffer recirculation results showing neutrophil CXCR-1 expression after exposure to buffer 
circulated through modified aminated Gambro AN69 fibers. 
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Figure 36. NERB buffer recirculation results showing neutrophil CXCR-2 expression after exposure to buffer 
circulated through modified aminated Gambro AN69 fibers. 
 
Whole blood recirculation was only collected at the extended time point after neutrophil 
isolation due to errors in the staining procedure. After neutrophil isolation, free IL-8 
downregulation was present in both CXCR-1 and CXCR-2, with hAlbumin control module treated 
neutrophils closely matching baseline blood. IL-8 module treated neutrophils experienced 
significant downregulation in CXCR-1 and CXCR-2, both approaching but not achieving the 
downregulation levels of free IL-8. CXCR-1/2 downregulation is shown in Figure 37 and Figure 
38. 
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Figure 37. Neutrophil CXCR-1 expression after recirculation through modified aminated Gambro AN69 
fibers. 
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Figure 38. Neutrophil CXCR-2 expression after recirculation through modified aminated Gambro AN69 
fibers. 
 
Boyden chamber chemotaxis testing was completed with isolated neutrophils after 
recirculation. These results are shown in Figure 39. Baseline untreated blood and free IL-8 controls 
were comparable to previous testing, with strong migration towards all chemoattractants in 
untreated blood and migratory shutoff towards 5nM IL-8 and GRO-α in the free IL-8 control. 
Neutrophils treated by both the hAlbumin control module and IL-8 test module exhibited similar 
migratory behavior to untreated blood. 
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Figure 39. Neutrophil migration in Boyden chamber chemotaxis assay after recirculation through modified 
aminated Gambro AN69 fiber modules with PEG spacer. 
 
The third test with Gambro-PEG fibers included some additional washing. An overnight 
5% single pass BSA wash, in addition to shell side wash solution to purge unbound IL-8. However, 
additional washing did not eliminate leached IL-8 induced downregulation in the NERB assay. 
Results in Figure 40 and Figure 41 show the IL-8 test module induced both CXCR-1 and CXCR-
2 downregulation compared to baseline blood and the hAlbumin control. Free IL-8 induced 
downregulation exceeded the test module and was comparable to past NERB tests. 
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Figure 40. NERB buffer recirculation results showing neutrophil CXCR-1 expression after exposure to buffer 
circulated through modified aminated Gambro AN69 fibers. 
 
Figure 41. NERB buffer recirculation results showing neutrophil CXCR-2 expression after exposure to buffer 
circulated through modified aminated Gambro AN69 fibers. 
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Whole blood recirculation results are shown in Figure 42 and Figure 43. These results 
indicate that the IL-8 module treated neutrophils has reduced CXCR-1/2 expression compared to 
baseline blood and hAlbumin control module treated neutrophils. The free IL-8 positive control 
had the anticipated high levels of both CXCR-1 and CXCR-2 downregulation. The IL-8 module 
treated neutrophil downregulation levels approached, but did not match free IL-8 positive control 
samples. 
 
 
Figure 42. Neutrophil CXCR-1 expression after recirculation through modified aminated Gambro AN69 
fibers. 
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Figure 43. Neutrophil CXCR-2 expression after recirculation through modified aminated Gambro AN69 
fibers. 
 
Boyden chamber chemotaxis testing was completed after whole blood perfusion and neutrophil 
isolation. The results of this test are shown in Figure 44. Unmodified baseline blood showed 
minimal chemokenesis and strong migration towards all chemoattractants. Free IL-8 positive 
control showed reduced migration towards 5nM IL-8 and GRO-α, but maintained migratory 
behavior towards other chemoattractants, including fMLP. Both the IL-8 module and hAlbumin 
control showed minimal changes from untreated baseline blood. However, the hAlbumin module 
treated neutrophils exhibited increased chemokenesis and a reduction in migration towards fMLP. 
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Figure 44. Neutrophil migration in Boyden chamber chemotaxis assay after recirculation through modified 
aminated Gambro AN69 fiber modules with PEG spacer. 
 
4.3.2.3 Stop flow configuration 
A stop flow experiment was completed to determine whether high shear rate was 
preventing neutrophils for interacting with immobilized IL-8 on the fiber surface. This experiment 
only analyzed CXCR-1/2 surface expression, not NERB or chemotaxis. Fibers were tested with 
Gambro-PEG immobilization and standard washing. Whole blood recirculation samples were 
collected every 15 minutes to get a better understanding of receptor expression over time. 
Whole blood recirculation results show significant CXCR-1 and CXCR-2 downregulation at 60 
minutes (Figure 45 and Figure 46). CXCR-1 downregulation begins at the first, 15 minute, time 
point but continues to increase through 60 minutes. It appears as if increased recirculation time 
may lead to a small amount of additional downregulation. CXCR-2 downregulation remained 
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stable from 15 through 60 minutes and appears to have reached a maximum. CXCR-1 and 
CXCR-2 downregulation are equivalent for both continuous and stop flow conditions. 
Downregulation of the modules appears to lag behind free IL-8 due to the nature of recirculation 
versus soluble IL-8.  
 
Figure 45. Neutrophil CXCR-1 expression after recirculation through IL-8 modified aminated Gambro AN69 
fibers with different flow conditions.  
 109 
 
Figure 46. Neutrophil CXCR-2 expression after recirculation through IL-8 modified aminated Gambro AN69 
fibers with different flow conditions. 
 
4.3.3 Additional washing protocols and leaching evaluation 
An IL-8 ELISA was used to quantify IL-8 leaching from fibers. A 5% BSA buffer was recirculated 
in place of whole blood then effluent was measured to determine the quantity of soluble IL-8 being 
released from the fibers after washing. These leaching values provide guidance to quickly iterate 
wash protocols without blood testing. Results of ELISA testing with multiple wash configurations 
is shown in Figure 47. Initial whole blood recirculation tests utilized a Tween-20 wash with 
overnight 5% BSA wash to remove non-covalently bound IL-8. In Gambro AN69 fibers, this wash 
configuration led to 1820 pg/mL IL-8 concentration. Fresenius fibers led to only 45 pg/mL. The 
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rate of IL-8 leaching from Gambro fibers led to receptor downregulation in the NERB assay, while 
Fresenius fibers had no downregulation. High salt washing was evaluated with Gambro fibers, 
with and without the overnight 5% BSA wash. Washing was conducted both inside and outside of 
the dialyzer fibers. This wash led to a reduction in IL-8 leaching, but the leaching rate was still 
significantly higher than the Fresenius rate. 
 
 
Figure 47. IL-8 concentration in buffered solution after 60 minute recirculation with various wash protocols. 
4.4 DISCUSSION 
This chapter discusses development of the NeRD module. Multiple device configurations were 
evaluated and tested using a progression of techniques used to analyze and track device 
performance. PMP oxygenator fibers and aminated dialyzer fibers provided by Fresenius and 
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Gambro were each evaluated. Flow cytometry was used to measure CXCR-1 and CXCR-2 
downregulation after whole blood recirculation through devices. Additionally, a modified Boyden 
chamber test was developed to quantify neutrophil chemotaxis after isolation. IL-8 leaching was 
evaluated using a NERB buffer recirculation assay and IL-8 ELISAs. While advances were made 
in device performance, no configuration was capable of inducing functionally relevant levels of 
CXCR-1 and CXCR-2 downregulation while limiting soluble IL-8 leaching.  
Early testing attempted to leverage PMP oxygenator fibers with a chitosan spacer, which 
has been previously used for enzyme immobilization [160]. Testing of monolayer IL-8 
immobilizations with a direct glutaraldehyde cross linker showed no IL-8 activity and limited IL-
8 loading capacity. Addition of a chitosan crosslinker has the advantage of increasing amine 
density, offering some flexibility to reduce steric hindrance, and generating a three dimensional 
structure to facilitate greater IL-8 loading capacity. This approach was only possible on oxygenator 
fibers, where blood flow is outside the fibers, due to chitosan’s high viscosity which would occlude 
dialyzer fibers. Whole blood recirculation testing of these samples showed CXCR-1/2 
downregulation compared to baseline blood in IL-8 module samples. However, the 
downregulation was present in the albumin control module as well, indicating the immobilized IL-
8 was not fully responsible for the downregulation. Chemotaxis testing showed that the observed 
level of downregulation was unable to cause the intended reduction in migration towards IL-8, 
actually an increase in migration was observed, potentially due to priming of the neutrophils. As 
new immobilization techniques were established, development moved towards dialyzer fibers. The 
dialyzer fibers were hypothesized to leverage neutrophil margination, which potentially increases 
neutrophil interaction with immobilized IL-8. Dialyzer fibers, with reduced priming volume, also 
present a higher effective IL-8 presentation due to a higher surface area to volume ratio. 
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Use of a PEG spacer was adopted in place of chitosan to increased immobilized protein 
flexibility as well as address potential protein denaturation that can occur with use of 
glutaraldehyde. The PEG immobilization occurs in aqueous conditions as close to physiological 
pH, increasing the chances of maintaining protein activity after immobilization. Testing of this 
immobilization was completed on PMP hollow fibers and dialysis fibers provided by both 
Fresenius and Gambro. PMP-PEG fibers experienced CXCR-1/2 downregulation in both the IL-8 
and albumin control modules. However, unlike the glutaraldehyde immobilization, there was a 
significant increase in CXCR-2 downregulation in the IL-8 module compared to control (Figure 
25). This indicates IL-8 is at least partially responsible for the downregulation. However, 
chemotaxis testing showed no functional change resulting from this downregulation (Figure 26). 
These results indicated more protein activity or interaction was required to achieve a functional 
benefit from the device. 
 Both Gambro and Fresenius fibers were evaluated with the PEG immobilization. Both 
fibers are aminated versions of widely used dialysis fibers. Fresenius fibers, with standard Tween-
20 and BSA wash protocol, did not register CXCR-1/2 downregulation in the NERB assay. This 
result was supported by a relatively low IL-8 buffer leach rate of 45pg/ml. These indicate that IL-
8 leaching is not an issue with these fibers as the small amount of IL-8 coming off the fibers does 
not cause significant IL-8 downregulation. These Fresenius fibers generated significantly more 
CXCR-1 and CXCR-2 downregulation than baseline, with downregulation of 37% and 35% 
respectively (Figure 29 and Figure 30). However, the hAlbumin control, also induces 
downregulation compared to baseline, indicating flow conditions, contaminants, or material 
characteristics of the fiber are also contributing to CXCR-1/2 downregulation. While 
downregulation is greater than control, the levels do not match the IL-8 positive control, and 
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Boyden chamber chemotaxis assay results indicate the surface receptor changes did not result in 
functional changes to neutrophil migration (Figure 31). It is hypothesized that while IL-8 was 
immobilized on the surface, the quantity and activity were insufficient to achieve migratory 
shutoff. 
 Gambro fibers are manufacturing from an acrylonitrile and sodium methallylsulfonate 
copolymer. These formulation leads to high binding and retention of charged proteins [169]. With 
the same washing protocol as Fresenius fibers the NERB assay registered significant levels of 
CXCR-2 downregulation (Figure 36), indicating IL-8 leaching was occurring. ELISA data 
supported the occurrence of leaching, with an IL-8 concentration of 1820 pg/mL, more than 40 
times greater than Fresenius fibers. With leaching, this configuration did induce significant CXCR-
1/2 downregulation with whole blood recirculation. One chemotaxis assay registered a pronounced 
migratory shutoff effect (Figure 34), but a second donor did not replicate this finding (Figure 39), 
indicating the result is not consistent. Increased washing, with shell side rinsing, extended times, 
and use of high salt concentration washing could not reduce the leaching rate to a level comparable 
to the Fresenius fibers which would not register on the NERB assay. 
The stop-flow conditions were tested to determine if the flow conditions were limiting 
neutrophil’s ability to interact with immobilized IL-8. Flow of whole blood with shear rates that 
are similar to physiological post-capillary venules are hypothesized to generate leukocyte 
margination. With this phenomena, neutrophils and other white blood cells are forced towards the 
lumen walls by red blood cells. This margination is intended preferentially increase the neutrophil 
interaction with the wall as well as decreasing cell velocity, allowing more time for neutrophils to 
interact with immobilized IL-8. However, it is possible that, without integrins co-immobilized on 
the fiber surface, neutrophils will have difficulty interacting with immobilized IL-8. Intermittently 
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stopping flow allows for margination to be established, followed by a period of time for neutrophils 
to intimately interact with the immobilized IL-8. CXCR-1/2 expression results shown in Figure 45 
and Figure 46 indicate there is no significant difference between continual and stop-flow. It is 
possible stop-flow offered a small increase in receptor downregulation due to increased interaction, 
but this affect would be counteracted by the decrease in whole blood throughput. Further 
optimization may offer a small increase in total downregulation, but overall the continuous flow 
condition appears ideal and would be easier to implement in the clinic. 
 Use of IL-8 to modulate neutrophil behavior is challenging. Low levels of IL-8 exposure 
(below 50 ng/mL) will activate neutrophils and increase chemotaxis towards IL-8, while high 
concentrations (100 ng/mL) result in migratory shutoff [170]. The values required for migratory 
shutoff are three to four orders of magnitude higher than what is expected in vivo, even for septic 
patients [157]. This indicates even low levels of CXCR-1/2 expression on receptors may be enough 
to result in migration towards IL-8. Achieving such high effective levels of IL-8 concentrations 
without any IL-8 leaching is challenging, particularly due to decreases in IL-8 activity after 
immobilization. The following chapter, on alternate approaches attempts to address these 
limitations with alternate device concepts. 
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In conclusion, a variety of potential configurations were evaluated to construct a neutrophil 
reprogramming device. This device is hypothesized to cause CXCR-1/2 downregulation and 
desensitization to reduce neutrophil migration towards IL-8 using immobilized IL-8 within the 
extracorporeal device. Fiber material, immobilization chemistry, wash protocol, and flow 
parameters were all adjusted in an attempt to find a combination with sufficient IL-8 activity to 
cause the desired results. However, no configurations were able to generate sufficient IL-8 activity 
to cause the desired effects. In the next chapter alternate device configurations which attempt to 
address the shortcomings of the current approach will be discussed.  
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5.0  ALTERNATIVE CONCEPTS FOR EXTRACORPOREAL TREATMENTS OF 
SEPSIS....             
Testing and evaluation of the NeRD device, described in the previous chapter, provided 
information about the advantages and limitations of an extracorporeal system to modulate 
leukocyte behavior. Among the advantages highlighted in the previous chapter, such a system 
potentially offers the ability to alter white blood cell behavior in a well control-microenvironment, 
preventing side effects associated with systemic delivery of pharmaceuticals.  However, while 
evaluating the system with IL-8 immobilization, it became clear that achieving high levels of 
activity with an immobilized ligand would be challenging. This chapter describes some alternative 
approaches which may leverage the systems advantages and address the limitations. Only 
preliminary testing of these approaches has been completed and the discussion will focus on 
potential future testing and device concepts. 
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5.1 METHODS 
5.1.1 Adsorptive column 
A recirculation flow loop was constructed as described in 4.2.3. An additional unaminated control 
minimodule with 25 AN69 fibers was added immediately downstream of the protein modified 
module. The portion of the loop with modules in series is shown in Error! Reference source not 
ound.. ELISA testing (Section 4.2.5) as well as buffer and whole blood recirculation testing (4.2.7 
and 4.2.8) were completed to evaluate this setup for IL-8 leaching and ability to modulate 
neutrophil behavior.  
 
 
Figure 48. Adsorptive AN69 column in series with protein modified module. 
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5.1.2 Adsorptive column construction 
Packed bead columns were evaluated in place of the AN69 fiber columns to remove leaching IL-
8. Columns with 1ml volume were packed with Cytosorb adsorbent beads (Cytosorbents, 
Monmouth Junction, NJ). A fine mesh was secured on the inlet and outlet to prevent beads from 
leaving the column. As shown in Error! Reference source not found., luer connectors on either 
nd of the column allow for the column to be incorporated into the recirculation loop. 
 
Figure 49. Packed bead column filled with adsorptive beads. 
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5.1.3 Infusion / Adsorption device configuration 
An alternative device configuration relies on a constant infusion of IL-8 into a secondary reservoir, 
where IL-8 interacts with neutrophils within the extracorporeal circulation, before being removed 
by an adsorptive column. This loop configuration is shown in Figure 50. After the recirculated 
fluid is removed from the primary reservoir, a T-junction facilitates infusion of IL-8. An infusion 
pump with 1 mL syringe slowly infuses IL-8 solution at a rate of 20ng/ml/hr. The secondary 
reservoir consists of a tube with 1 mL volume which contains a static mixer. A packed bed column 
is at the outlet of the secondary reservoir to remove infused IL-8 before returning to the primary 
reservoir. This configuration is evaluated using ELISAs, NERB buffer recirculation, and 
recirculation with pre-isolated neutrophils resuspended in DPBS. 
 
 120 
 
Figure 50. Infusion adsorption recirculation test loop. 
5.2 RESULTS 
5.2.1 Adsorptive column 
Addition of an adsorptive scavenging module, in series with an IL-8 immobilized Gambro-PEG 
fiber module, significantly reduced effective IL-8 leaching. An IL-8 ELISA with this configuration 
showed that the leaching rate dropped from 1820 to 32 pg/mL after a 60 minute recirculation. This 
value is equivalent to the IL-8 leaching rate present in the Fresenius-PEG IL-8 immobilized fibers. 
These results are shown in Figure 51. 
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Figure 51. IL-8 leaching with inline scavenging module. 
 
NERB buffer recirculation testing supported the low IL-8 leaching rate measured using the 
ELISA assay. As shown in Figure 52 and Figure 53, CXCR-1 and CXCR-2 downregulation was 
minimal in neutrophils combined with buffer from IL-8 and hAlbumin modified devices when 
scavenging modules were used in series. 
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Figure 52. NERB buffer recirculation results showing neutrophil CXCR-1 expression after exposure to buffer 
circulated through modified aminated Gambro AN69 fibers with inline scavenging module. 
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Figure 53. NERB buffer recirculation results showing neutrophil CXCR-2 expression after exposure to buffer 
circulated through modified aminated Gambro AN69 fibers with inline scavenging module. 
 
Whole blood recirculation CXCR-1/2 receptor expression are shown in Figure 54 and 
Figure 55. The free IL-8 positive control induces substantial CXCR-1/2 downregulation, which 
remains consistent from 60 minutes through the neutrophil isolation process. The hAlbumin 
module CXCR-1/2 expression remains comparable to baseline blood throughout the entire 
experiment. The IL-8 module induced 42% and 44% CXCR-1 and CXCR-2 downregulation 
respectively at 60 minutes. However, these values returned to near baseline blood during 
neutrophil isolation. 
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Figure 54. Neutrophil CXCR-1 expression after whole blood recirculation through modified aminated 
Gambro AN69 fibers with inline scavenging module. 
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Figure 55. Neutrophil CXCR-2 expression after whole blood recirculation through modified aminated 
Gambro AN69 fibers with inline scavenging module. 
 
Boyden chamber chemotaxis assay results (show free IL-8 treated neutrophils exhibit 
reduced migration towards 5nM IL-8 and GRO-α, but maintained migration to other 
chemoattractants compared to baseline. hAlbumin and IL-8 module treated samples exhibited 
migration comparable to baseline blood.  
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Figure 56. Neutrophil migration in Boyden chamber chemotaxis assay after recirculation through modified 
Gambro AN69 fibers in series with a scavenging module. 
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5.2.2 Infusion/Adsorption 
The infusion adsorption testing replaced the IL-8 modified module with an infusion of soluble IL-
8 which is removed from by either an unmodified AN69 fiber module or column of packed 
Cytosorb beads. IL-8 ELISA testing was used to determine which removal technique was most 
effective. Data indicated both the AN69 and Cytosorb columns removed large amounts of infused 
IL-8, but the Cytosorb column more effectively removed IL-8 at 30 minutes, with undetectable 
levels of IL-8 in solution compared to 236 pg/mL in the AN69 column. At 60 minutes AN69 
column IL-8 levels decreased to 111 pg/mL and the Cytosorb column increased to 150 pg/ml, as 
shown in Figure 57. 
 
 
Figure 57. ELISA results of IL-8 infusion adsorption loops with either AN69 or Cytosorb bead columns for 
IL-8 removal. Historic results of IL-8 leaching in immobilized columns is also included. 
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Infusion adsorption recirculation testing was completed with a 20 ng/ml/hr IL-8 infusion 
rate and Cytosorb adsorptive columns. NERB data, shown in Figure 58 and Figure 59, indicated 
CXCR-1/2 downregulation was occurring in both IL-8 infusion and control infusion loops. IL-8 
infusion CXCR-1/2 downregulation was greater than the infusion control at 30 minutes, but the 
two samples were reached equivalent levels of downregulation at 60 minutes. 
 
 
Figure 58. NERB buffer recirculation results showing neutrophil CXCR-1 expression after exposure to buffer 
circulated through IL-8 infusion or control infusion loops with Cytosorb columns. 
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Figure 59. NERB buffer recirculation results showing neutrophil CXCR-2 expression after exposure to buffer 
circulated through IL-8 infusion or control infusion loops with Cytosorb columns. 
 
Isolated neutrophils were circulated through infusion adsorption loops for 60 minutes. No 
CXCR-1/2 downregulation was observed in these samples compared to control. A small increase 
in CXCR-1/2 expression was present in these samples at 60 minutes, potentially indicating 
neutrophil priming or activation. These findings are shown in Figure 60 and Figure 61. 
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Figure 60. Neutrophil CXCR-1 expression after whole blood recirculation through recirculation loops with 
IL-8 infusion and Cytosorb adsorptive columns. 
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Figure 61. Neutrophil CXCR-2 expression after whole blood recirculation through recirculation loops with 
IL-8 infusion and Cytosorb adsorptive columns. 
 
Boyden chamber chemotaxis results (Figure 62) indicate the expected neutrophil behavior 
in untreated baseline blood and free IL-8 positive control. However the infusion control and IL-8 
infusion samples show increased chemotaxis. This is particularly evident in infusion control 
samples, which show increased chemotaxis towards all chemoattractants. 
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Figure 62. Neutrophil migration in Boyden chamber chemotaxis assay after recirculation through 
recirculation loops with IL-8 infusion and Cytosorb adsorptive columns. 
5.3 DISCUSSION 
This chapter discusses alternate approaches and future steps to modulate neutrophil behavior 
within an extracorporeal circuit. These techniques intend to build off the findings of the previous 
studies. Preliminary testing was completed for the techniques which relied on an absorptive 
column to remove unbound IL-8. Other concepts, which do not include preliminary data, will be 
discussed below. The preliminary data shows that it is possible to generate CXCR-1/2 
downregulation using a combination of immobilized IL-8 column in series with an absorptive 
column, but Boyden chamber chemotaxis results indicate the level of downregulation is not 
significant enough to generate migratory shutoff. Further studies are required to optimize the 
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infusion/adsorption test setup, but preliminary results indicate that the required infusion rate of IL-
8 would be higher than the adsorptive column capacity. Use of alternate ligands to generate 
different neutrophil behaviors should be explored to address some of the current device’s 
limitations. 
Testing in the previous chapter showed that PEG-IL-8 immobilization on Gambro AN69 
fibers exhibited significant CXCR-1/2 downregulation, but IL-8 leaching could not be completely 
eliminated. Removal of all unbound IL-8 is extremely difficult due to charged sulfonate groups 
designed to bind highly charged middle molecular weight proteins such as IL-8. Due to leaching, 
it was difficult to differentiate downregulation induced by immobilized IL-8 from leached soluble 
IL-8. Testing in this chapter, with addition of a scavenging module in series is able to differentiate 
the source of this downregulation by leveraging the charged protein binding characteristics of 
AN69 fibers. ELISA results show more than 20x reduction in leached IL-8; reducing leaching to 
a level that does not induce CXCR-1/2 downregulation. Whole blood recirculation with this 
configuration results in measurable CXCR-1/2 downregulation at 60 minutes, but the neutrophils 
fully recovered during the neutrophil isolation process. Unsurprisingly, these fully recovered 
neutrophils did not show any change in migratory behavior. This is the first instance where CXCR-
1/2 recovery of such magnitude was observed. It is possible that other instances, where 
downregulation remained constant through isolation, were able to maintain receptor levels due to 
low levels of leached IL-8 which were in solution during isolation. During the isolation process, 
neutrophils remain in their initial solution until near the end of the process, meaning any soluble 
IL-8 remain in solution until the final resuspension. While neutrophil surface receptor recovery 
makes functional testing difficult, fast recovery may be beneficial in a potential device due to its 
rapid reversibility. 
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Both unmodified AN69 fiber modules and Cytosorb bead columns were evaluated for IL-
8 removal. Both established their ability to remove significant amounts of infused IL-8 through 
ELISA testing with the IL-8 infusion setup. Infusion adsorption testing was completed using 
Cytosorb bead columns because of their higher theoretical loading capacity. Not only does a 
packed bead column have a higher overall surface area than fiber module of similar priming 
volume, but Cytosorb beads have a porous structure, allowing proteins like IL-8 to penetrate the 
beads. AN69 fibers may have similar a similar microstructure within their pores, but the fiber’s 
primary purpose is solute transport, not adsorption. Either column has limitations to total protein 
loading capacity, limiting IL-8 infusion rate. Testing with elevated IL-8 infusion rates led to IL-8 
levels in solution above the leaching rate of AN69 fibers, which is known to trigger CXCR-1/2 
downregulation in the NERB assay. The Cytosorb beads used for evaluation were taken from 
samples previously provided to the lab at an unknown time, and may have degraded over time. 
NERB results from the infusion control (Figure 58 and Figure 59), which induce downregulation, 
indicate the beads may have had a contaminant or pathogen which caused neutrophil activation. 
This contaminant may have counteracted effects of the IL-8 infusion. This testing should be 
repeated once fresh Cytosorb columns are obtained. 
Many of the challenges of this approach are a result of the elevated IL-8 levels necessary 
to achieve receptor downregulation and desensitization. While these levels are much easier to 
obtain in free solution than immobilized on a surface, removing all soluble IL-8 difficult, 
particularly if a simple, single pass, system is desired. The infusion adsorption system can be 
altered in a number of way to improve efficacy. First infusion rate can be increased, requiring a 
larger adsorption column. The current infusion rate of 20 ng/ml/hr or 200 ng/mL over the hour 
long recirculation, are significantly lower than the 1 ug/mL IL-8 which is added to the free IL-8 
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positive control. Increased IL-8 infusion will require a scaled increase in adsorptive column 
surface area. The adsorptive column size in addition to cost of infused IL-8 provide 
commercialization challenges if this approach were scaled up.  Another approach to increasing 
performance is increasing secondary reservoir volume, modulating flow rate, or introducing 
periods of no flow to increase dwell time. The 1 mL secondary reservoir leads to an average dwell 
time of only 1 minute. A larger reservoir may increase IL-8 interaction with neutrophils, increasing 
device performance. 
Considering many of the device issues are related to use of IL-8, it is worth considering 
use of alternate ligands in its place. While desensitization generally requires high concentrations 
of the target ligand, which would lead to similar challenges, the systems designed in this 
dissertation would apply to direct receptor signaling. Generally cytokine signaling functions at 
pico to nano-molar concentrations, rather than micro molar concentrations required for 
desensitization.  The approaches discussed can be used to prevent delivery of the ligands to 
systemic circulation, preventing adverse effects and increasing the ability to reverse and stop 
treatment. For example, use of lipoxin A4 (LXA4) may reduce neutrophil chemotaxis and facilitate 
resolution of inflammation [171,172]. Other cytokines, or even low exposures of IL-8, can be used 
to prime and stimulate neutrophils to increase chemotaxis for patients suffering from 
immunoparalysis. Further exploration of alternate ligands should be completed to determine 
potential targets that can influence leukocytes in the extracorporeal circuit, but would benefit from 
limited introduction into systemic circulation. 
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6.0  ZWITTERIONIC SURFACE TREATMENT OF POLYMETHYLPENTENE 
HOLLOW FIBER MEMBRANES FOR RESPIRATORY ASSIST  
The following chapter includes work from a manuscript draft titled Development of Zwitterionic 
Sulfobetaine Block Copolymer Conjugation Strategies for Reduced Platelet Deposition in 
Respiratory Assist Devices.  It has been submitted to Langmuir and is currently under review. 
All extracorporeal devices, particularly those with large surface (e.g. artificial lungs), 
increase the risk of thrombotic complications. Novel surface coatings, such as zwitterionic 
sulfobetaine (SB) will help minimize this risk. However, functionalization of the PMP fiber surface 
and development of conjugation chemistry is required to implement this coating. The Medical 
Devices Lab and collaborators have previously developed techniques to amine functionalize 
materials, specifically polypropylene (PP) and polymethylpentene (PMP) oxygenator fibers, using 
plasma vapor deposition with allylamine [161,173]. This discusses a new method to hydroxyl 
functionalize materials using oxygen plasma vapor deposition and implement an SB surface 
coating. Zwitterionic surface coatings were evaluated on PMP fibers to determine stability of 
complete coatings under device flow conditions. After further development of PMP coated hollow 
fibers, future work may adapt these surface coatings to other blood contacting device such as the 
NeRD. 
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6.1 INTRODUCTION 
Balancing required blood anticoagulation while maintaining adequate levels of hemostatic activity 
is a major challenge that presents with a wide variety of blood contacting medical devices. This 
issue is particularly challenging in extracorporeal circuits such as respiratory assist devices, which 
expose patient blood to large surface areas (~2 m2) of synthetic material [174–178]. Blood contact 
with these artificial surfaces results in activation of the coagulation cascade, and platelet deposition 
onto the foreign surfaces [179,180], leading to reduced device performance and emboli formation 
[181–183]. Additionally, prolonged support may deplete the patient of critical coagulation factors 
and reduce platelet numbers, causing systemic hemostatic issues [184,185]. Physicians manage 
these thrombotic challenges with use of anticoagulants, most commonly systemic administration 
of heparin. However excess anticoagulation, particularly when administered systemically, may 
cause bleeding problems [186,187]. In fact bleeding issues are the most common complication in 
extracorporeal membrane oxygenation (ECMO), occurring in between 10-30% of cases, and the 
thrombotic complications that anticoagulation is meant to blunt, commonly lead to reduced device 
lifespan [182,187–189]. The risks associated with limited device blood biocompatibility and the 
pharmacologic interventions utilized to address this limitation clearly restrict the broader adoption 
of life saving extracorporeal therapies. 
A great deal of effort has been directed at improving the hemocompatibility of 
extracorporeal circuits, by better pharmacologic management, more efficient circuit design and 
improved surfaces. These advances have led to broader use of dialysis and increasing use of ECMO 
and respiratory dialysis, particularly for low flow CO2 removal
 [174,183,190–192]. ECMO and 
respiratory dialysis devices utilize gas permeable hollow fiber membranes (HFMs) to add oxygen 
and remove carbon dioxide from blood independent of the lung. Innovations in HFMs, such as the 
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introduction of polymethylpentene (PMP) HFMs in oxygenators, have facilitated extended patient 
support periods by preventing plasma leakage into the fiber lumen, which was common in older 
generation, porous wall polypropylene fibers [193]. PMP fibers greatly extended the circuit life of 
the oxygenator by resisting plasma leakage, but thrombotic deposition on fiber surfaces remained 
as a problem. Local anticoagulation using citrate is a potential solution, but it requires a more 
complex loop, restricted flow rates and its use is not widespread [194,195]. 
Surface modification of synthetic fiber materials provides a potential resolution to the 
coagulation dilemma. Direct coating of the fiber may allow for local inhibition of thrombotic 
deposition, reducing the need for systemic anticoagulation and the resulting complications for the 
patient. Heparin coating of blood-contacting surfaces in extracorporeal perfusion circuits is 
common, but it is debatable as to the how much this surface modification has resulted in clinical 
benefit [196]. Surface conjugation of polymers bearing zwitterionic groups (e.g. 
phosphorylcholine, sulfobetaine (SB), carboxybetaine) have been described and examined as anti-
fouling, non-thrombogenic and anti-bacterial materials [197–200], but many of these approaches 
are limited by cost and stability [201–203]. Given the potential for zwitterionic surface 
modification to provide improved hemocompatibility in many instances, development of new 
surface modification strategies using this basic concept are warranted where durability and cost 
efficiency are design features. 
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Figure 63. Approaches for pre-functionalization of PMP hollow fibers & post-conjugation of SB molecules. 
 
In this chapter, a new SB block copolymer with N-hydroxysuccinimide ester groups 
(SBNHS) was synthesized to simplify conjugation to functionalized PMP HFMs. Two coating 
strategies, which pair PMP surface functionalization and zwitterionic molecule conjugation, were 
developed and evaluated. The first strategy employs plasma-enhanced chemical vapor deposition 
(PECVD) to generate amine functional groups on the PMP fiber surface that are subsequently 
conjugated to functional SB block copolymers, building upon our previous work with PP fibers 
[162]. A second strategy utilized surface hydroxylation [204] to conjugate an SB block copolymer 
with siloxane groups (Figure 63). The zwitterion-modified PMP surfaces were evaluated for acute 
thrombotic deposition, surface modification stability under anticipated shear flow conditions, and 
for the impact of the surface modification on gas exchange performance. These coatings address 
the shortcomings of currently available alternatives as they are stable under high fluid shear stress, 
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do not inhibit membrane transport, and employ economically attractive SB moieties as opposed to 
phosphorylcholine. This study evaluates the coatings for use specifically in respiratory assist 
devices, but the coatings are shown to be effective on several clinically relevant materials.  
6.2 MATERIALS AND METHODS 
6.2.1 Materials 
Commercially available polymethylpentene hollow fibers (Oxyplus™; OD: 380 µm, ID: 
200 µm) were obtained from Membrana GmbH (Wuppertal, Germany). N-(3-Sulfopropyl) -N-
(methacryloxyethyl)-N,N-dimethylammonium betaine (SMDAB) monomer, Acrylic acid N-
hydroxysuccinimide ester (AANHS), 4-Cyano-4-(phenylcarbonothioylthio) pentanoic acid 
(CPPA as a chain transfer agent), 4,4′-azobis(4-cyanopentanoic acid) (V-501) (ACPA, initiator), 
3-aminopropyl-trimethoxysilane (APSi), N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDC), N-Hydroxysuccinimide (NHS), 2,2,2-trifluoroethanol (TFE), and buffer 
reagents were purchased from Sigma-Aldrich. Methacrylic acid (MA, Sigma-Aldrich) was 
distilled before its use. [Sulfo-succinimidyl-4-O-(4,4´-dimethoxytrityl)-butyrate] (Sulfo-SDTB) 
was purchased from prochemonline. Bovine blood was freshly harvested from a local 
slaughterhouse and anticoagulated with heparin. Gentamycin (0.1g/mL) was added and blood was 
filtered (Haemonetics SQ40s 40 µm transfusion filter) to remove particulates. PBS was added to 
adjust hemoglobin to 12 ± 1 g/dL and glucose was adjusted to 10 mmol/dL ± 5 mmol/dL according 
to ISO 7199:2009. 
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6.2.2 Synthesis of SB block copolymers with functional groups 
SB block copolymers with functional groups (COOH or NHS) were synthesized using a standard 
reversible addition fragmentation chain transfer (RAFT) polymerization technique previously 
described [162]. Briefly, after being dissolved in TFE solvent, SB prepolymer was synthesized 
from SMDAB monomer, CPPA chain transfer agent (CTA) and V-501 (ACPA) initiator at a 
determined molar ratio (SMDAB: CTA: ACPA= 10:1:0.5) to yield SB-CTA. Argon gas was 
bubbled into the solution for 30 min to remove oxygen, then the solution was sealed under argon 
for the duration of the synthesis. After stirring for 15 h at 70°C, the synthesized product was 
precipitated into anhydrous methanol. The obtained pink gel-like product (SB-CTA prepolymer) 
was further rinsed with excess methanol and dried in a vacuum oven for 24 h. Next, macro SB-
CTA and MA or AANHS monomer was dissolved in TFE at a predetermined molar ratio (SB-
CTA:MA=1:10 for SBMA, SB-CTA: AANHS=1:10 for SBNHS). After adding ACPA initiator 
and bubbling argon gas into the solution for 30 min, the reaction mixture was stirred for 15 h at 
70°C. Following precipitation in anhydrous methanol, centrifugation, and rinsing to remove 
unreacted reagents, the synthesized SBMA or SBNHS block copolymers were obtained after 
vacuum drying. The siloxane functionalized SB block copolymers (SBSi or SBNHSi) were also 
prepared from the block copolymers after reaction with APSi via a standard EDC/NHS conjugation 
technique [162,205].  
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6.2.3 PMP fiber functionalization and characterization 
6.2.3.1 Hollow fiber functionalization 
Unmodified polymethylpentene (PMP) hollow fiber membranes were either amine or hydroxyl 
functionalized using plasma enhanced chemical vapor deposition (PECVD) with a PVA TePla Ion 
40 system. Amine functionalization was completed according to a technique established by 
Arazawa et al [163]. Briefly, hollow fiber membrane samples, in a mat format, were cut to size 
(102 cm2), washed with 0.5% Tween-20 in 100 mM phosphate buffer pH 8.5, then rinsed with 
deionized water. Upon adding samples, the chamber was evacuated to 50 mTorr. Allylamine was 
introduced to the chamber at a rate of 180 mL/min and 300 W of power at 150 Hz and a 20% duty 
cycle was introduced for times ranging from 1 (A1) to 5 min (A2). Samples were removed and 
immediately rinsed three times with 0.5% Tween-20 in 100 mM phosphate buffer pH 8.5 then 
thoroughly rinsed with deionized water. Hydroxyl groups were generated using oxygen 
plasma[204]. PMP hollow fiber samples were prepared in a similar manner to amine 
functionalization, but after establishing 50 mTorr in the chamber, oxygen was added to the 
chamber at 500 mL/min then powers ranging from 100-600 W at 150 Hz and 20% duty cycled 
was applied for 30-300 sec. Additional materials, including polycarbonate sheet (Makrolon®, 
Bayer CropScience Ltd.) and a polyvinylchloride tubing (Fisherbrand Clear PVC Tubing, Fisher 
Scientific Inc.), were functionalized in the same manner. 
6.2.3.2 Quantification of surface amine groups using sulfo-SDTB amine assay                      
Surface amine density was varied by adjusting plasma exposure time. Increased time exposure 
raises amine density, but may adversely inhibit gas exchange performance. 4 mL of 2.4 mM Sulfo-
SDTB was added to a 16 cm2 fiber sample and incubated at room temperature for 2 hr. Fibers were 
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then washed with 0.5% Tween-20 in deionized water to remove unbound reagent. 35% perchloric 
acid was added to cleave immobilized sulfo-SDTB and induce color change. Harvested solutions 
were read using a spectrometer (Thermo Genysis UV-Vis) at 498nm and amine concentration was 
calculated using a standard curve. 
6.2.3.3 SB block copolymer conjugation        
To prepare an SB block copolymer conjugated surface (PMP-A-SBMA or PMP-A-SBNHS), the 
amine functionalized PMP fiber (PMP-A) mats were immersed in a container with 0.1 wt% of 
aqueous SBNHS (NHS functionalized) solution or SBMA (carboxyl functionalized) with 
EDC/NHS [162] and placed on a rocker at RT for 15 hr. For PMP-H-SBSi or PMP-H-SBNHSi, 
the hydroxyl functionalized PMP fiber (PMP-H) mats were immersed SBSi and SBNHSi solutions 
that were reacted with APSi in situ condition. The surface compositions were analyzed by X-ray 
photoelectron spectroscopy (XPS) using a Surface Instruments S-probe spectrometer with a 
takeoff angle 55°, performed at NESAC-BIO, University of Washington. Additional materials, 
including polycarbonate sheet (Makrolon®, Bayer CropScience Ltd.) and a polyvinylchloride 
tubing (Fisherbrand Clear PVC Tubing, Fisher Scientific Inc.), were modified and analyzed in the 
same manner.  
6.2.3.4 In vitro blood contact test and platelet deposition characterization                             
Surface platelet deposition was analyzed after prolonged material contact with fresh whole ovine 
blood as described in previous studies [160,162,206]. In short, whole ovine blood was collected 
by jugular venipuncture with an 18½ gauge needle feeding directly into a syringe with a citrate 
solution (10mM/mL). The first 3 mL of blood were discarded to ensure sample uniformity. 
National Institutes of Health guidelines for the care and use of laboratory animals were observed 
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for all donor sheep, and all procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC). PMP fiber swatches were cut from fiber mats into 5 cm long segments for 
analysis. The fiber ends were sealed using a hot glue gun to prevent blood from reaching the inner 
lumen. Samples were sterilized by ethanol emersion then washed with DPBS. The fibers were then 
placed into a vacutainer tube (BD Vacutainer, no additives) filled with 5 mL of the fresh, citrated 
ovine blood and rocked for 3 h at 37°C using a hematology mixer (Fisher Scientific, Pittsburgh, 
PA).   
After removal from the tubes, samples were rinsed with DPBS at least 10 times, according 
to the previously described protocol, in preparation for scanning electron microscopy (SEM, JEOL 
USA model JSM-6330F) analysis [162]. In addition to direct visualization of the surface, a lactate 
dehydrogenase assay (LDH, Cytotoxicity Detection Kit, Clontech Laboratories, Inc.) was used to 
quantify platelet deposition [162]. 
The results are presented as mean ± standard deviation (SD). Data were analyzed by one-
way ANOVA followed by a post hoc Neuman-Keuls testing. Significant differences were 
considered to exist at p <0.05. 
6.2.3.5 SB coated fiber stability testing 
PMP hollow fibers (238 cm2) were functionalized and coated with SBMA, SBSi, SBNHS, or 
SBNHSi as detailed above. Fiber mats were potted directly into polycarbonate mini-modules using 
5 min epoxy (Devcon, Danvers, MA). The mini-modules have been scaled from full sized 
oxygenator devices and simulate flow conditions for gas exchange 21,22 
Mini-modules with open ports were sterilized using a standard ethylene oxide (EtO) 
sterilization cycle. Peristaltic pumps and L/S 16 Masterflex tubing were used to circulate 200 mL 
PBS with sodium azide through the modules at 45 mL/min for 2 wk at 37°C. The PBS solution 
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was replaced at one week. After recirculation was complete, samples were removed from modules 
and unrolled. Randomly selected 1 by 1 cm2 fiber mats were cut and sent for XPS analysis and 
LDH platelet deposition testing. 
6.2.3.6 Gas exchange testing of SB coated hollow fibers 
Scaled polycarbonate gas exchange mini-modules were constructed from uncoated and SBNHS 
and SBNHSi modified fibers as described above. 5 min epoxy potting was used to separate the gas 
and fluid pathways. A gas exchange recirculation loop (see Figure 64) was assembled to measure 
CO2 removal from freshly drawn bovine blood. The fluid side gas exchange loop contained (in 
series) a 1L compliant blood reservoir, peristaltic pump, Sorin Lilliput 2 D902 pediatric de-
oxygenator, heat exchanger, and a mini-module before returning to the fluid reservoir. The de-
oxygenator sweep gas was composed of carbon dioxide, oxygen, and nitrogen. These ratios were 
adjusted to set inlet blood CO2 partial pressure at 50 mmHg ± 5 mmHg as measured by a 
RapidPoint 305 blood gas analyzer (Siemans, Deerfield, IL).  
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Figure 64. In vitro gas exchange analysis setup using a scaled down gas exchange module. Not shown are the 
CO2, N2 and O2 gas lines, the oxygen gas flow meter, condenser, and CO2 analyzer. 
 
The oxygen sweep gas originates in a pressurized oxygen tank regulated by mass flow 
controller before passing through the mini-module. Sweep gas then passed through a condenser, 
vacuum pump, and CO2 analyzer. Triplicates of unmodified control fibers, PMP-SBNHS, and 
SBNHSi were each tested in triplicate at a blood flow rate of 45 mL/min. The sweep gas flow rate 
was modulated to maintain a 3000 ± 100 ppm CO2 concentration at the gas outlet. A one way 
ANOVA analysis was completed using SPSS 23 (IBM Analytics, Armonk, NY) with a p 
value<=0.05 
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6.3 RESULTS 
6.3.1 Synthesis of SB block copolymers with functional groups 
Chemical structures were confirmed using proton nuclear magnetic resonance (1H NMR, 
BrukerBiospin Co., Billerica, MA). For the newly synthesized SBNHS in D2O, peaks were: δ 
(ppm) = 0.90-1.30 (α-CH3), 1.70-2.20 (CH2C), 2.25-2.35 (CH2CH2SO3), 2.80-2.85 (CH2-CH2), 
2.90-3.00 (CH2CH2SO3), 3.20-3.40 (N(CH3)2), 3.50-3.85 (CH2N(CH3)2CH2) and 4.35-4.55 
(OCH2). The peak area integration ratio of 2.80-2.85 (CH2-CH2, m) and 4.35-4.55 (OCH2, e) was 
used to define the polymer composition. A SBNHS block copolymer, which was synthesized with 
a 2:1 monomer feed ratio of SBDMB and AANHS, resulted in a peak area integration ratio (e/m) 
of 2.7. After APSi conjugation (SBNHSi), the peak from the NHS groups, δ (ppm)=2.80-2.85 
(CH2-CH2, m) was decreased and new peaks were measured at 0.65-0.75 (CH2-Si, n) and 1.20-
1.30 (OCH3, p), indicating the presence of conjugated APSi (Figure 65). 
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Figure 65. 1H NMR spectra of functional zwitterionic block copolymers (SBNHS or SBNHSi). 
 
6.3.2 HFM amine functionalization 
PMP fibers aminated with PECVD showed that the plasma treatment time period (A1: 1 min, 
A2: 5 min) could be adjusted to vary HFM amine density, as measured by the sulfo-SDTB amine 
assay and XPS analysis (Table 5). A2 showed a 3% increase in N percentage compared to A1, 
indicating enhanced amination. All amine functionalized HFM conjugations were completed 
using 5 minute time, hereby referred to as PMP-A. 
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Table 5. Atomic percentages for plasma treated hollow fiber surfaces as determined by X-ray photoelectron 
spectroscopy. 
 
 
 
6.3.3 OH functionalized fiber SEMs 
A new functionalization approach using hydroxyl groups (-OH) was developed. Unlike surface 
amine groups, hydroxyl groups are not anticipated to negatively impact biocompatibility and may 
increase the conjugation efficiency and loading of SB block copolymer. For hydroxylated PMP 
fibers (PMP-H) prepared by oxygen plasma treatment using PECVD, excessive power settings 
may damage the PMP fiber surface, so SEM images were taken for visual inspection (Figure 3). 
Damage to the fiber surface was observed in the 600 W, 30 sec and 5 min samples. Reduction of 
power to 100 W allowed for a plasma exposure time of 60 sec without visual signs of surface 
damage. X-ray photoelectron spectroscopy (XPS) (Table 5) was used to confirm surface 
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hydroxylation. The oxygen percentage peaked at 12% ± 0.4% in the 100 W, 60 sec sample. All 
hydroxylated PMP HFM conjugations were completed using 100W, 60 sec sample, hereby 
referred to as PMP-H. 
 
 
Figure 66. Surface morphology change in PMP HFMs after exposure to O2 plasma (PECVD) at indicated 
power levels and exposure times. 
 
6.3.4 SB block copolymer conjugation and platelet deposition on HFMs after ovine blood 
contact 
SB block copolymers SBMA, SBNHS, SBSi, and SBNHSi were directly conjugated to 
functionalized PMP fibers (PMP-A: 5 min or PMP-H: 100 W, 60 s). The loading capacity of 
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SBMA onto the fibers can be measured by observing changes in the surface sulfur (S) content. 
XPS analysis results in Table 6 show S content ranging from 1.0± 0.1% to 1.2± 0.1%, compared 
to 0.3 for PMP-A and undetectable levels for PMP-C and PMP-H. 
 
Table 6. Atomic percentages for SB block copolymers modified hollow fiber surfaces as determined by X-ray 
photoelectron spectroscopy. 
 
 
Platelet deposition on the controls, pre-functionalized, and modified PMP hollow fibers 
after contact with fresh ovine blood for 3 hr is shown in Figure 67, Figure 68, and Figure 69.  
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Figure 67. Scanning electron micrographs of PMP control and the modified surfaces after contact with 
citrated ovine whole blood for 3 h at 37°C. 
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Figure 68. Scanning electron micrographs of PMP control and the modified surfaces after contact with 
citrated ovine whole blood for 3 h at 37°C. 
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Figure 69. Scanning electron micrographs of PMP control and the modified surfaces after contact with 
citrated ovine whole blood for 3 h at 37°C. 
 
The control (PMP-C) and pre-functionalized surfaces (PMP-A and PMP-H) showed large 
quantities of deposited platelets with aggregates spread uniformly over the entire fiber surface. 
The average amount of deposition on PMP-A samples showed a higher deposition than the PMP-
C as well as PMP-H based on the SEM observation and LDH assay results (Figure 70). Platelet 
deposition and the aggregates were dramatically reduced on all of the SB block copolymer 
conjugated surfaces compared to control and pre-functionalized surfaces (p<0.05).  
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Figure 70. Platelet deposition on a fiber mat unit (1 cm2), including binding fibers, after contact with fresh 
ovine blood for 3 h at 37°C as determined by a lactate dehydrogenase (LDH) assay (*P<0.05  vs. PMP-C, 
PMP-A2 and PMP-H controls,  n=3). 
 
6.3.5 SB coating stability testing 
The surface compositions of coated fibers were also measured after exposure to elevated fluid 
shear levels for 2 wk in PBS at 37°C (Table 7).  
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Table 7. Atomic percentages for the 2wk rinsed HFM surfaces as determined by X-ray photoelectron 
spectroscopy. 
 
 
Both PMP-A-SBMA (2 wk) and PMP-H-SBSi (2 wk) decreased over 50% compared to 
pre-flow exposure (Table 6). SBNHS and SBNHSi coated surfaces better preserved surface S, 
remaining above 0.9 ± 0.1% and 1.0 ± 0.1% respectively. SEM images and LDH assay results 
(Figure 71 and Figure 72) also provide evidence of coating integrity, exhibiting significantly 
reduced platelet deposition in both samples compared to PMP aminated controls (p<0.05).  
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Figure 71. Scanning electron micrographs of stability tested PMP hollow fibers (PBS rinsed for 2 wk) after 
contact with fresh ovine blood for 3 h at 37°C. 
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Figure 72. Platelet deposition on the stability tested PMP hollow fibers (PBS rinsed for 2 wk) after contact 
with fresh ovine blood for 3 h at 37°C as determined by a lactate dehydrogenase (LDH) assay (*P<0.05  vs. 
the controls). 
 
6.3.6 Gas exchange testing 
Gas exchange performance of hollow fibers was evaluated by examining carbon dioxide removal 
in a scaled experiment which simulates a clinical gas exchange setup. CO2 removal rates were 
normalized using inlet CO2 partial pressure to account for variations over the test span, then 
divided by fiber surface area. Only PMP-A-SBNHS and PMP-H-SBNHSi modifications were 
 159 
evaluated due to their superior stability characteristics. Removal rates are shown in Figure 73.  The 
unmodified control fiber removal rate of 248 ± 6 (mL/min/m2) is comparable to previous testing 
using scaled modules [162,p.20]. Aminated SBNHS coating samples (PMP-A-SBNHS) exhibited 
a 6% reduction in mean CO2 removal rate, while hydroxyl activated SBNHSi fibers (PMP-H-
SBNHSi) did not vary substantially from the mean control fiber CO2 removal rate. The statistical 
analysis determined a p-value of 0.08.  
 
 
Figure 73. CO2 removal rate by HFMs in bovine blood using a scaled down gas exchange module (n=3). 
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6.3.7 Polycarbonate and PVC surface modification 
Both unmodified polycarbonate and polyvinylchloride (PVC) control surfaces showed 
widespread platelet deposition with a spread morphology and platelet aggregates after 3 h 
contact with fresh ovine blood contact, although polycarbonate visually exhibited less platelet 
deposition and aggregation than PVC, as shown in Figure 74. 
 
Figure 74. Scanning electron micrographs of blood-contacted polycarbonate (PCB), polyvinylchloride (PVC) 
and the SBNHSi modified surfaces after contact with citrated ovine whole blood for 2 h at 37°C. 
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After the surface modification using SBNHSi, the amount of platelet deposition was 
reduced on both surfaces by up to 95% as shown in the LDH assay results Figure 75. 
 
 
Figure 75. Platelet deposition as determined by a lactate dehydrogenase (LDH) assay after contact with 
citrated ovine whole blood for 2 h at 37°C (*P<0.01  vs. PCB-H and PVC-H controls). 
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6.4 DISCUSSION 
This manuscript describes the development of zwitterionic surface modification approaches for 
use in extracorporeal blood-contacting medical devices such as artificial lungs. Two surface 
functionalization techniques, designed for amine or hydroxyl functionalized HFM surfaces 
respectively, were evaluated with the objective of designing a robust and simple process 
compatible with coating an entire extracorporeal circuit. The modified HFMs were shown to 
significantly reduce acute platelet deposition from whole blood, even after 2 wk exposure to 
continuous fluid flow. Additionally, gas exchange studies performed with the modified HFMs 
showed no significant reduction in gas transport, a critical feature for the application of this 
methodology in respiratory assist devices.  
Amine functionalization of porous polypropylene hollow fibers has been studied by our 
group in the past [160,162]. With this approach, allylamine monomer was deposited on the fiber 
surface using PECVD, generating stable amine groups, but also decreasing fiber permeance [207]. 
Excess allylamine deposition may lead to decreased gas exchange performance, particularly if 
paired with a high molecular weight coating. Additionally, unreacted amines may result in 
increased platelet deposition. Variations of hydroxyl functionalization have been implemented in 
a variety of prototype extracorporeal devices [74,208]. With PMP fibers, excessive oxygen plasma 
runs the risk of damaging the thin outer fiber film which prevents plasma leakage [209]. This 
damage can be seen in SEMs of HFMs treated with elevated power and time settings (Figure 66: 
600 W / 30 sec, 600 W / 5 min & 100 W / 120 sec), but was not present at the lower power settings 
(100 W / 60 sec) which were used for conjugation. The selected instrument settings did not present 
visible fiber damage and also exhibited the highest surface oxygen content (12.0 ± 0.4 %, Table 
5), indicating these parameters balance avoidance of fiber damage and degree of functionalization. 
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For decades, various polymers bearing zwitterionic groups have been developed and 
studied as anti-fouling, non-thrombogenic and anti-inflammatory materials [197–200]. Studies by 
Cook [210–212], Li [208], and Gong [213] have incorporated zwitterionic coatings into prototype 
artificial lung devices with success on the bench. Phosphorylcholine (PC) polymer coatings have 
also been incorporated into CE-approved oxygenators (ALONE ECMO, EUROSETS, Italy), but 
there are still many potential improvements that may benefit clinical efficacy and application in 
the challenging extended perfusion periods associated with ECMO support. PC surface coatings 
may not be suitable for long term use due to the ability of the phosphoester group to be hydrolyzed 
[203]. Additionally, PC coatings are relatively expensive and difficult to handle compared to other 
zwitterionic polymers [201,202]. These limitations of PC coatings challenge widespread 
integration into extracorporeal devices, leading to exploration of alternative zwitterionic polymers. 
SB polymers in particular have shown promise, with comparable improvements in 
hemocompatibility and platelet deposition to PC counterparts at a lower price with higher stability. 
[162,199,201,214]  
 
 
 
 
 
 
 
 
 164 
Our previous work developed functional zwitterionic PC macromolecules and low 
molecular weight (LMW <10,000) sulfobetaine (SB) block copolymer with carboxyl groups 
(SBMA-COOH) for polypropylene HFM surface modification [162]. These compounds are water 
soluble and can be conjugated onto an aminated polypropylene HFM to reduce thrombotic 
deposition without significantly inhibiting gas performance. Although the previous experimental 
coatings using the LMW SB block copolymer were promising, they have not been evaluated using 
PMP HFMs which are increasingly used in commercial oxygenators and are critical for the 
extended blood contact in chronic respiratory assist devices. The modifications have also not been 
tested for extended exposure to fluid flow rates commonly seen in clinical practice or on other 
material surfaces included in a typical extracorporeal loop (e.g. cannula, tubing and device housing 
material).  
Given that the application of extracorporeal oxygenators is necessarily associated with 
continuous exposure to flowing blood and wall shear stresses, the surface modification stability is 
of concern, and the instability of common device coatings such as heparin and PC have been 
documented [214–216]. Many techniques have been developed to improve stability and these show 
short term improvements in thromboresistance [217–219] , but few studies have examined efficacy 
after long term exposure to anticipated fluid shear conditions. In this study, a 2 week perfusion 
with buffered saline was completed to simulate the extended operating conditions becoming more 
prevalent in ECMO and more recent CO2 removal devices. Additionally, prior to the recirculation 
studies, the modules employed were EtO sterilized to simulate commercial devices. Results in 
Table 7 indicate previously developed coatings (SBMA and SBSi), which did not incorporate 
multiple active NHS groups, exhibited a reduction in surface sulfur groups, suggesting leaching of 
the conjugate from the HFM or degradation of the zwitterionic compounds. However, SBNHS and 
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SBNHSi coatings did not experience the same degree of reduction, indicating greater stability 
under the anticipated operating shear and temperature. This stability, which has not been exhibited 
by other coatings, would be critical to achieving prolonged reductions in systemic anticoagulation. 
However, it should be noted that extended perfusion with patient blood would be a more rigorous 
situation, given the array of protein (especially enzyme) and cellular components that could act to 
foul or degrade the surface activity. The resistance of the SB modified surfaces to resist such 
interactions would potentially act to retard this effect. 
Adding any coating to HFMs raises concerns of decreased gas exchange due to increased 
gas transfer resistance. Higher molecular weight coatings in particular run this risk. In this study 
the employment of RAFT polymerization allows for generation of well-controlled, low molecular 
weight block copolymers with versatile functional groups. The block copolymer synthesis strategy 
is particularly versatile as it could be used in one approach (with SBNHS) to provide for direct 
conjugation to amines on the target surface, or in an alternate approach, to generate a polymer such 
as SBNHSi to react with surface hydroxyl groups. Gas exchange testing showed no statistical 
difference in CO2 removal rates between modified and control HFMs. Comparable gas exchange 
evaluation on coated PMP fibers was completed by Huang [208] on PC coated PMP fibers. This 
testing showed a 15% reduction in mean CO2 removal rate. 
The majority of studies developing thromboresistant coatings have focused on a single 
material and application [162,208,213]. However, most extracorporeal circuits are composed of a 
variety of materials and surfaces which may contribute to thrombus formation and subsequent 
embolization. To evaluate the versatility of the reported surface modification approach, acute 
thromboresistance was evaluated for two materials commonly found in non-gas transferring 
surfaces included in extracorporeal devices. Polycarbonate, which is commonly used for injection 
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molded housings, and PVC, which is a widely used tubing material, were functionalized and 
modified under the same parameters as the PMP HFMs. With the effectiveness of the modification 
strategy shown on these surfaces, the data suggest that it may be possible to uniformly modify all 
blood contacting surfaces in an extracorporeal circuit, to further improve the blood 
biocompatibility and potentially allow for the reduction in systemic anticoagulation.  
While this report has established a technique capable of reducing acute platelet deposition 
on a variety of materials commonly used in respiratory assist devices, without significantly 
reducing device performance, there are a number of limitations that should be noted. First, the 
surface modification strategy has only been evaluated in vitro and for limited contact periods with 
anticoagulated animal blood. In vivo testing would be the next step to more fully verify device gas 
transfer performance and thromboresistance. The notion that systemic anticoagulation might be 
reducible in clinical practice with such surface modifications would similarly need to first be 
evaluated in a large animal model. As noted previously, stability testing established modification 
stability at shear rates comparable to that experienced in full-sized devices, however it is unknown 
how the coating would perform after exposure to the proteases and high protein concentrations 
present in blood, not to mention with extended contact with leukocytes and platelets. While a range 
of functionalization and conjugation parameters were evaluated, a complete optimization was not 
completed and further improvements in performance and stability of the reported modifications 
may be possible. Finally, all testing was completed on scaled-down devices or HFM swatches. It 
is believed the process would scale to full sized devices, but a strategy for surface modification 
would need to be developed. For instance, determining whether the fibers would be modified 
independently of the device housing or whether an assembled oxygenator could be modified.  
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6.5 CONCLUSIONS 
This study reports two techniques for the functionalization and subsequent conjugation of SB block 
copolymers to PMP HFMs with the intention of reducing thrombus formation in respiratory assist 
devices. Amine or hydroxyl functionalization of HFMs was accomplished using PECVD and the 
generated functional groups were then conjugated to newly synthesized SBNHS or SBNHSi block 
copolymers. The modified HFMs showed markedly reduced platelet deposition from whole ovine 
blood, stability under the fluid shear of anticipated operating conditions and uninhibited gas 
exchange performance. Additionally, the functionalization and conjugation techniques were 
shown to reduce platelet deposition on other materials which are common in extracorporeal circuits 
such as polycarbonate and PVC tubing. This flexible surface modification approach may thus 
allow for coating of an entire blood contacting extracorporeal circuit. Improvements in the 
thromboresistance of the blood-contacting surfaces in large extracorporeal devices intended for 
chronic support are essential to allow for the reduction of anticoagulation levels in the supported 
patients. Without such advancements, the implementation of these devices will be hampered since 
the technology will continue to be associated with limited patient mobility, a high-level of patient 
oversight and management, and substantial patient morbidity. 
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7.0  SUMMARY AND CONCLUSIONS 
While research continues to improve our understanding of the biological mechanisms of sepsis, 
few treatments address sepsis’ underlying mechanism. Similarly, advances to materials and surface 
coatings have improved the safety and efficacy of extracorporeal devices, but most devices still 
rely on formulations developed in the previous decade. While the use of respiratory dialysis, 
ECMO, and dialysis continues to expand, there are many other potential applications for 
extracorporeal devices to selectively modulate blood cell behavior. The combination of these two 
concepts can potentially lead to a novel range of new treatments and improvements of current 
devices, particularly in the area of acute inflammatory conditions. Much of the work in this 
dissertation focused on development of an extracorporeal device platform, which incorporates a 
covalently immobilized cytokine on the device surface. The specific device envisioned could 
“reprogram” blood cell response to improve outcomes for the target disease state. 
 The first goal of this dissertation was to develop a mechanistic computational model to 
study the role of IL-8 induced CXCR-1/2 neutrophil surface receptor downregulation and in the 
progression of sepsis. The model, which contains 16 ordinary differential equations and 43 
parameters, was constructed based on a simplified mechanistic representation of CXCR-1/2 
activation. Both neutrophil receptor level dynamics and systemic parameters were coupled with 
multiple activated neutrophil phenotypes which control pathogen load and adverse tissue damage. 
The model was calibrated using experimental data from baboons administered a two-hour infusion 
of E coli and followed for a maximum of 28 days. After model calibration, implementation of an 
extracorporeal device, such as the NeRD, which modulates CXCR-1/2 expression was tested in 
silico. The findings suggest that interventions aiming to modulate phenotypic composition are time 
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sensitive, with treatment efficacy quickly diminishing if not introduced within 15 hours of 
infection. Significant harm is possible with short treatments, which are predicted to reduce 
survival. Overall this model supports the development of a device capable of modulating CXCR-
1/2 expression to treatment acute inflammatory conditions like sepsis and further development of 
the computation model may help guide device development and target patient populations. 
The next goal of this dissertation was to develop and evaluate an extracorporeal device 
which uses immobilized IL-8 to reprogram neutrophils. The reprogramming would attenuate 
neutrophil’s chemotactic response to IL-8 and reduced neutrophil induced organ damage in acute 
inflammatory conditions such as sepsis.  A variety of device materials, immobilization methods, 
and wash parameters were evaluated in an attempt to find a device configuration which maximizes 
IL-8 activity without resulting in functionally relevant levels of IL-8 leaching from the device. 
While significant levels of CXCR-1 and CXCR-2 downregulation were achieved, this effect was 
insufficient to cause consistent migratory shutoff to IL-8 as measured by a Boyden chamber 
chemotaxis assay. This approach appears to be limited by the required elevated levels of active IL-
8 required to induce migratory shutoff. Learnings from this set of experiments were used to 
develop alternate device concepts described in the next dissertation chapter. 
During development of the NeRD, limitations of the current design and possibilities for 
alternatives were considered. These alternatives were summarized in the third dissertation chapter. 
In order to address challenges associated with limited activity of immobilized IL-8 and issues with 
IL-8 leaching, experiments were conducted with absorbent columns to remove soluble IL-8 from 
recirculation. An infusion adsorption device concept was conceptualized, which intentionally 
infused soluble IL-8 into the extracorporeal circuit, but removed the IL-8 before it could be 
delivered to systemic recirculation. Initial testing, with infusion rates set to minimize IL-8 
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leaching, was unable to achieve migratory shutoff, but further optimization of the system may 
allow elevated IL-8 infusion rates and a greater impact on neutrophil chemotaxis. Another concept 
involves utilizing either the immobilized or infusion adsorption concept with an alternate ligand 
which operates at lower concentrations. While further research and testing is required to find an 
ideal ligand for this system, there is still potential to utilize the advantages of an extracorporeal 
circuit. 
The final goal of this dissertation was to implement a zwitterionic macromolecule coating 
on PMP HFMs. Two techniques of PMP HFM functionalization and subsequent conjugation of 
SB block copolymers were evaluated for their ability to reduce platelet deposition. Both fiber 
configurations resulted in 80-95% reductions in platelet deposition from whole ovine blood, 
stability under shear stress, and uninhibited gas exchange performance relative to unmodified 
HFMs. Additionally, the functionalization and SBNHSi conjugation technique was shown to 
reduce platelet deposition on polycarbonate and poly(vinyl chloride), two other materials 
commonly found in extracorporeal circuits. The observed thromboresistance and stability of the 
SB modified surfaces, without degradation of HFM gas transfer performance, indicate that this 
approach is promising for longer term pre-clinical testing in respiratory assist devices and may 
ultimately allow for the reduction of anticoagulation levels in patients being supported for 
extended periods.  
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7.1 FUTURE VISIONS 
Sepsis remains one of the largest challenges in modern medicine. Progress has been made in sepsis 
treatment, but it has been incremental rather than revolutionary. The long list of failed technologies 
shows how difficult it is for a concept to be translated from bench to bedside. Understanding of 
the underlying biology and immune system’s role in sepsis has led to many potential therapies, but 
most fail at or before reaching blinded clinical testing. The patient diversity and wide range of 
symptoms presented in sepsis, in addition a high frequency of elderly patients with comorbidities, 
is one of the largest challenges that clinicians and innovators face. This challenge will only increase 
as medical technology extends the life of patients and improves outcomes of other conditions. 
 Improved diagnosis and division of the patient population may help improve outcomes of 
new technologies in sepsis. Treatments must be developed to address both hyper and hypo-
inflammatory aspects of sepsis and identifying the correct patient characteristics will be critical to 
these treatment’s success. Computational modeling can help support these decisions in the clinic; 
considering more inputs and data than would be otherwise possible, algorithms can be powerful 
tools to guide treatment and inform physicians. Development of rapid diagnostics to provide 
personalized treatment for patients would provide data to better inform both physicians and 
computational model inputs. Advances in microfluidics and diagnostics makes this a possibility. 
Improved selection of patients may also help address the difficulties of generating evidence in 
clinical studies. Selecting ideal patients, from a small subset of the population, may help therapies 
reach the market.  
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Even with a history of failed therapies, modulation of the immune system offers much 
promise for the future of sepsis treatments. Current therapies fail to address the underlying cause 
of sepsis, and approaches that modulate immune response offer the possibility of returning a 
patient to immune homeostasis. Many available therapies run the risk of overcorrecting the 
immune system, therefore a treatment that is either reversible or has active feedback may be 
necessary for a successful treatment. A system like the NeRD, that can be halted, with its effects 
degrading quickly, would be a promising advancement. The concept of selectively targeting cells 
within an extracorporeal circulation, without the therapeutic every reaching systemic circulation 
could be applied to many different cell signaling pathways while minimizing risks associated with 
systemic drug delivery. 
Use of extracorporeal devices has become increasingly safe over the last 10-20 years, but 
continues to be associated with significant risks. Even occasional complications associated with 
bleeding or thrombus formation can counteract the advantages offered by lifesavings devices. This 
applies not only to potential immune-modulating technologies, but the next generation of 
respiratory assist devices. Improvements to human factors, usability, and training has significantly 
reduced the incidence of these complications, but the continued use of systemic anticoagulation 
will always be associated with negative side effects. The use of local anticoagulation is a logical 
next step for extracorporeal devices. Citrate anticoagulation, while not widely used, provides an 
option for lower flow extracorporeal devices. However, this approach is not widely used, and the 
complexity and potential harm if used incorrectly, may limit its widespread adoption. Additionally, 
citrate prevents coagulation, but may not limit any immune or complement activation that occurs 
in these circuits. Novel surface coatings may provide a significant improvement over currently 
available options. Coatings can be applied to an entire blood contacting surface area, limiting both 
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thrombus formation and immune activation. Heparin coatings, which are regularly used, provide 
some assistance, but these are quickly overwhelmed and degraded after blood contact. A stable 
coating with similar or greater affects has the possibility of drastically reducing complications of 
extracorporeal devices by minimizing or eliminating the use of systemic anticoagulation.  
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